CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc. 1 Clinical Protocol 
Protocol Title:  An Open-Label Study to Evaluate the Safety of Teplizumab  
(PRV -031) in At -Risk Relatives Who Develop  Type 1 Diabetes  
Protocol Number:  PRV -031-002 
Version  Number: 1.0 
Compound:   Teplizumab  
Study Phase:   2 
Short Title:    At-Risk Extension 
Sponsor Name:  Provention Bio, Inc. 
Legal Registered Address:  
P.O. Box 666 
Oldwick, NJ 08858 
Regulatory Agency Identifier Number(s) : 
IND: 102,629 
EudraCT:  TBD 
NCT:
 [STUDY_ID_REMOVED] 
Approval Date: 02 December  2019 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc. 2 DOCUMENT HISTORY  
Document  Date  
Original Protocol  (version 1.0)  02-Dec-2019
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc. 3 Table of Contents  
1. Protocol Summary ..........................................................................................................6  
1.1. Synopsis ............................................................................................................................6  
1.2. Schema  ..............................................................................................................................7  
1.3. Schedule of Events ............................................................................................................8  
2. Introduction ...................................................................................................................10
2.1. Type 1 Diabetes (T1D) ...................................................................................................10  
2.1.1.  Definition and metabolic characteristics of Type 1 diabetes 
mellitus  ............................................................................................................................10  
2.1.2.  Natural History of Type 1 Diabetes ................................................................................10  
2.2. Teplizumab Overview.....................................................................................................11  
2.2.1.  Results from the TN -10 St udy ........................................................................................12  
2.3. Safety Experience with Teplizumab  ...............................................................................14  
2.4. Use of Teplizumab in Children .......................................................................................17  
2.5. Benefit/Risk Assessment  ................................................................................................18  
3. Objectives and Endpoints  ............................................................................................19  
4. Study Design  ..................................................................................................................20  
4.1. Overall Design  ................................................................................................................20  
4.2. Scientific Rationale for Study De sign ............................................................................20  
4.3. Justification for Dose ......................................................................................................21  
4.4. End of Study Definition ..................................................................................................23  
5. Study Population ...........................................................................................................24  
5.1. Inclusion Criteria  ............................................................................................................24  
5.2. Exclusion Criteria  ...........................................................................................................24  
5.3. Enrollment ......................................................................................................................25  
6. Study Drug Dosing  ........................................................................................................26  
6.1. Study Drug Administered ...............................................................................................26  
6.2. Preparation/Handling/Storage/Accountability ................................................................26  
6.3. Concomitant Therapy .....................................................................................................27  
6.3.1.  Diabetes Management and Insulin Use  ...........................................................................27  
6.3.2.  Prophylactic Medications ................................................................................................27  
6.3.3.  Prohibited Medications ...................................................................................................28  
6.3.4.  Emergency Precautions  ...................................................................................................28  
7. Interruption or Discontinuation of Study Drug Treatmentand Part
icipant Discontinuation/Withdrawal  ............................................................30  
7.1. Interruption of Study Drug Treatment ............................................................................30  
7.2. Discontinuation of Study Drug Treatment......................................................................31  
7.3. Partici pant Discontinuation/Withdrawal from the Study ................................................32  
7.4. Lost to Follow-up............................................................................................................33  
8. Study Assessments and Procedures .............................................................................34  
8.1. Screening and Baseline Assessments  .............................................................................34  
8.1.1.  Screening (Visit -1) .........................................................................................................34  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc. 4 8.1.2.  Baseline Assessments and Initiation of Teplizumab Treatment 
(Visit 1)  ...........................................................................................................................34  
8.2. Post- Baseline Visits  ........................................................................................................34  
8.3. Efficacy Assessments  .....................................................................................................35  
8.3.1.  Metabolic Assessments  ...................................................................................................35  
8.3.2.  Mechanistic Outcome Assessments  ................................................................................35  
8.4. Safety Assessments  .........................................................................................................36  
8.4.1.  Adverse Events and Serious Adverse Events .................................................................36  
8.4.2.  Clinical Safety Laboratory Assessments  ........................................................................37  
8.4.3.  Physical Examinations ....................................................................................................38  
8.4.4.  Vital Signs and Infusion Reaction Monitoring ...............................................................38  
8.4.5.  Pregnancy  ........................................................................................................................38  
8.5. Pharmacokinetics and Immunogenicity ..........................................................................39  
8.6. Pharmacodynamics  .........................................................................................................39  
8.7. Genetics  ..........................................................................................................................39  
9. Statistical Considerations .............................................................................................40  
9.1. Statistical Hypotheses  .....................................................................................................40  
9.2. Sample Size Determination  ............................................................................................40  
9.3. Populations for Analyses ................................................................................................40  
9.4. Statistical Analyses  .........................................................................................................40  
9.4.1.  Primary Endpoint: Safety ................................................................................................40  
9.4.2.  Secondary Endpoints ......................................................................................................40  
9.4.3.  Handling Missing/Discontinued Participants .................................................................41  
9.5. Interim Analyses  .............................................................................................................41  
10. Supporting Documentation and Operational Considerations  ..................................42  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ................................................................................................................42
 
10.1.1.  Study-Specific Design Considerations ...........................................................................42  
10.1.2.  Investigator Responsibilities  ...........................................................................................42  
10.1.3.  Regulatory and Ethical Considerations ...........................................................................42  
10.1.4.  Informed Consent Process ..............................................................................................43  
10.1.5.  Data Protection ................................................................................................................44  
10.1.6.  Registration  of Clinical Studies and Disclosure of Results ............................................47  
10.1.7.  Required Pre-study Documentation ................................................................................47  
10.1.8.  Monitoring ......................................................................................................................48  
10.1.9.  Data Quality Ass urance  ..................................................................................................48  
10.1.10.  Source Documentation ....................................................................................................49  
10.1.11.  Case Report Form Completion  .......................................................................................49  
10.1.12.  Record Retention ............................................................................................................50  
10.1.13.  Study Completion/Termination  ......................................................................................50  
10.1.14.  Study Completion/End of Study .....................................................................................50  
10.1.15.  Study Termination ..........................................................................................................51  
10.1.16.  On-Site Audits  ................................................................................................................51  
10.2.  Appendix 2: Clinical Laboratory Tests Performed Locally ............................................52  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc. 5 10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .........................................................53  
10.3.1.  Definition of AE  .............................................................................................................53  
10.3.2.  Definition of SAE ...........................................................................................................54  
10.3.3.  Definition of AESI ..........................................................................................................55  
10.3.4.  Reporting and Follow-Up of AE and/or SAE .................................................................56  
10.4.  Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information  ...................................................................................................59
 
10.5.  Appendix 5: Abbreviations .............................................................................................61  
11. References  ......................................................................................................................64
In-Text T
ables  
Table 1: Grade of adverse events related to study drug ................................................................ 15  
Table 2: Adverse events by category and designated and possibly, probably, or definitely related 
to study drug. ................................................................................................................................ 16  
In-Text F
igures  
Figure 1: Effects of Teplizumab Treatment on Development of Type 1 Diabetes ....................... 13  
Figure 2: Percentage of KLRG1+TIGIT+CD8+ of total CD3+ T cells in the teplizumab and 
placebo treated participants........................................................................................................... 14  
Figure 3: Absolute lymphocyte counts in the study groups are shown over the first 7 weeks after 
enrollment ..................................................................................................................................... 17  
Figure 4: PK Simulation of 12-Day and 14-Day Dosing Regimens ............................................. 22  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc. 6 1. Protocol Summary
1.1. Synopsis
Protocol Title:   An Open -Label Study to Evaluate the Safety of Teplizumab  (PRV -031) in At -
Risk Relatives Who Develop  Type 1 Diabetes  
Short Title:  At-Risk Treatment Protocol 
Rationale: 
Teplizumab (also known as PRV -031, hOKT3γ1 [Ala -Ala], and MGA031) is a humanized 150-
kilodalton monoclonal antibody (mAb) that binds to the CD3- ε epitope of the T cell receptor . A 
recently completed TrialNet study (TN-10) demonstrated that teplizumab  significantly delayed the 
onset of clini cal diabetes in relatives at very high risk for type 1 diabetes (T1D). As teplizumab is 
predicted to preserve beta cell function, participants who were in the TN-10 trial and have 
subsequently develop ed clinical T1D after the conclusion of that trial, are eligible to enroll and 
receive teplizumab treatment  in this open- label study within  one year of their clinical T1D 
diagnosis.  
Objectives and Endpoint s 
Objectives  Endpoints  
Primary  
•To evaluate the safety and tolerability
of teplizumab treatment, administered
intravenously (IV) to participants in
the TN -10 trial who have developed
T1D.•Incidence of treatment -emergent
adverse events (TEAEs), adverseevents of special interest (AESIs), andserious adverse events (SAEs)
Secondary  
•To evaluate the pharmacokinetics
(PK) and immunogenicity of
teplizumab
•To evaluate whether teplizumab
treatment reduces the loss of β cells,
over 78 weeks (18 months), inindividuals with recent diagnosis ofT1D.
•To evaluate key clinical parameters ofdiabetes managemen t, including
insulin use, hemoglobin A1c (HbA1c),and clinically important hypoglycemicepisodes over 78 weeks•Levels of teplizumab in the serum and
anti-drug antibodies
•The area under the time-versus-concentration curve (AUC) ofC-peptide after a 4 -hour (4h) mixed-
meal tolerance test (MMTT), ameasure of endogenous insulinproduction and β cell function, over78 weeks
•HbA1c levels ; insulin use, defin ed as
a daily average dose in units perkilogram per day (U/kg/day ); and
frequency of clinically important
hypoglycemic episodes  over 7 8 weeks
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc. 7 Objectives  Endpoints  
• To evaluate whether treatment with 
teplizumab increases the frequency  of 
exhausted  T cells   • Frequency of CD8+  TIGIT+  KLRG1+ 
T cells  
 
Overall Design  
The study is a single -arm, multicenter, open- label clinical trial.  
Teplizumab -treated and placebo participants who were in the TrialNet TN -10 trial , have been 
diagnosed with T1D , and are able to start teplizumab treatment within 1 year of the T1D diagnosis 
are eligible to enro ll in this open -label study.  
Number of Participant s: 
Up to 30 participants may be enrolled in this study. 
Treatment  and Study Duration: 
All participants will receive a 12 -day course of teplizumab given through daily IV infusion.  
Participants will have a screening period of up to 4 weeks, a treatment period of 12 days, and a 
follow-up period of up to 78 weeks (18 months) from the first dose of treatment.  
1.2. Schema  
The study schema is noted below. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   8 1.3. Schedule of Events  
Week  -4 1 2 4 12 26 52 78 ET 
Month  -1 1 3 6 12 18 ET 
Day Screen11 2 3 4 5 6 7 8 9 10 11 12 28 84 182 364 546 ET 
Visit window  Not applicable  ±4 
days ±4 
days ±2 
wks ±2 
wks ±2 
wks 
Visit number  -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ET 
Inform ed consent/assent  X 
Inclusi on/exclusion criteria review  X X 
Medical history  X X X X X X X X X X X X 
Height (cm) & weight (kg)  X X X X X 
Vital signs2 X X X X X X X X X X X X X X X X X X X 
Physical exam (C=Complete; 
P=Partial)  C P P P P P P C 
Previous/ concomitant medications  X X X X X X X X X X X X X X X X X X X 
Adverse event review  X X X X X X X X X X X X X X X X X X X 
Teplizum ab dose calculatio n X 
Premedication  X X X X X X3 X3 X3 X3 X3 X3 X3 
Teplizumab administration4 X X X X X X X X X X X X 
Tuberculosis testing (PPD or IGRA)  X 
Chemist ry and LFTs5,6 X X X X X X X X X X X 
CBC with differential  and platelets5 X X X X X X X X X X X X X 
Teplizumab levels7 X X X X X X X X 
Anti-teplizumab antibodies7 X X X X X X X X 
EBV/CMV serology8 X 
EBV and CMV viral loads8 X X X 
HIV, HBV, HCV serology8 X 
4h MMTT9 X X X X X 
T1D autoantibodies  X 
Urine pregnancy test (WOCBP only)  X X X X X X X X 
Urine ketones10 
HbA1c  X X X X X X 
Mechanistic assessments11 X X X X X X X X 
Abbreviations: ALT=alanine aminotransferase, AST=aspartate aminotransferase, BP=blood pressure, BUN=blood urea nitrogen, CBC=complete blood count, 
CMV=cytomegalovirus, EBV=Epstein -Barr virus, EBNA= Epstein -Barr nuclear antigen , ET=early termination visit, HbA1c=hemoglobin A1c, HBV=hepatitis B virus, 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   9 HCV=hepatitis C virus, HIV=human immunodeficiency virus, Ig=immunoglobulin IGRA= interferon -gamma release assay, LDH=lactate dehydrogenase, MMTT= mixed -meal 
tolerance test, PPD=purified protein derivative, T1D=type 1 diabetes, WOCBP=women of childbearing potential  
Footnote
s: 
1. Enrollment must occur within 4 weeks of screening.
2. Vital signs include temperature, pulse, blood pressure , and respiration. On dosing days, vital signs should be collected pre -dose, 15 minutes  after the start of infusion , at the
end of infusion, and 60 minutes  after the end of infusion.
3. Pre-treatment medicati ons are required on Days 1-5 , optional on Days 6- 12.
4. Teplizumab dose: Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3 to 12: 850 μg/m2 daily.
5. These results must be reviewed prior to drug administration (see Section 8.1.2). CBC with differentials  are done locally.
6. Liver function tests (ALT, AST, LDH, alkaline phosphatase, total protein, albumin, total and direct bilirubin) and chemistries (sodium, potassium, chloride, CO 2, glucose,
BUN, creatine) are done locally.  Day 1 samples should be  obtained pre-dose.
7. Blood samples for the measurements of t eplizumab trough levels and anti -drug antibodies are to be obtained within 30 minutes before study drug infusion.
8. Serology assessments include EBV IgG  and IgM,  EBNA, CMV IgG  and IgM, HIV, HBV, and HCV are done locally . All particip ants, regardless of whether they are
seropositive  or seronegative  for EBV and CMV at screen ing, will be tested for  viral load  by the central lab  at the indicated visits .
9. MMTT: 4-hour samples should be collected pre-dose on Day 1.  Samples will be archived for possible future pro-insulin analysis.
10. In participants who have discontinued insulin therapy, urine ketones should be checked once daily.
11. Includes samples for RNA, plasma, serum, DNA, and measurement s of B and T cell number s and function to understand the effect of therapy on the immune system and
infectious disease.  Day 1 samples should be obtained pre-dose.
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   10 2. Introduction
2.1. Type 1 Diabetes (T1D)  
2.1.1. Definition and metabolic characteristics of Type 1 diabetes mellitus  
Type 1 diabetes mellitus (T1D) is an immune -mediated disease in which insulin- producing beta 
cells are completely or near completely destroyed, resulting in life -long dependence on exogenous  
insul
in.  It is a chronic and potentially disabling disease that represents a major public health and 
clinical concern.  
The number of patients being diagnosed with type 1 diabetes is increasing each 
year and is approaching an epidemic level in some cou ntries that track this information 
(Imperatore 2018 , EURODIAB 2000). 
Compared to individuals with the more common form of diabetes, Type 2 diabetes, the metabolic 
impairment in T1D is much more severe and the loss of insulin production more complete. 
Cont inuous
 exogenous insulin therapy is needed to prevent ketoacidosis and allow assimilation of 
food a
nd to maintain life. Most likely as a consequence of the absolute deficiency of insulin, 
glucos
e counter regulation (i.e. the hormonal response to insulin induced hypoglycemia) is 
impa
ired, and therefore, hypoglycemia is a frequent complication of the disease. The occurrence 
of hypoglycemia limits the ability to achieve near normal glucose control. The Diabetes Control 
and Complications T rial (DCCT) showed tha t the long- term complications could be reduced with 
near normal control of glucose levels but at the cost of an increased frequency of 
severe hypoglycemia (DCCT 1993). While there have been significant improvements in insulin 
delivery systems, 
such as continuous subcutaneous insulin infusions with insulin pumps, 
normal glucose control, particularly in children, is rarely achieved. Individuals with Type 1 
diabetes remain at risk for secondary end-organ complications including visual impairment and 
blindness, renal failure, vascular disease and limb amputation, peripheral neuropathy, 
stroke, acute risk for severe hypoglycemia, and others. Moreover, at the time of diagnosis, 
many individuals, and children in particular, suffer significant morbidity frequently 
requiring intensive care admission. Contemporary clinical data support the need for 
prevention of T1D: two recent studies identified loss of 17.7 and 14.2 life-years among men 
and women, respectively, who were diagnosed as children before age 10, and 11 and 13 life-
years lost for Scottish men and women diagnosed before age 20 (Livingstone 2015, Rawshani 
2018). Prevention of T1D remains, therefore, an important unmet medical need.   
2.1.2. Natu
ral History of Type 1 Diabetes 
Much is known about the natural history of the T1D disease process (Atkinson 2005). Although 
all
 people are susceptible, relatives of individuals with T1D are at much greater risk for 
devel
opment of the disease.  In the general population, approximately 0.3 % of individuals will 
develop T1D. In con trast, those with a relative with T1D have a 5% incidence of disease – a 15-
fold increase (Riley 1990).  Further risk stratification among family members depends upon 
genetic, immune and metabolic data (Sherr 2008).   
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   11 In genetically susceptible persons, T1D prog resses through asymptomatic stages prior to the 
devel
opment of overt hyperglycemia. These stages are characterized by the appearance of 
autoa
ntibodies (Stage 1) and then dysglycemia (Stage 2). In Stage 2, metabolic responses to a 
glucose load are impaired but other metabolic indices, for example, glycosylated hemoglobin, 
remain normal, and 
insulin treatment is not needed (Riley 1990). These immunologic and 
metabolic features can identify persons at high-risk for development of clinical disease; overt  
hyperglycemia, once it develops (Stage 3), requires insulin treatment.  
Based on data from the Diabetes Prevention Trial, type 1 diabetes (DPT -1) a nd other natural 
history studies, the risk for developing diabetes in relatives without the disease can be defined by 
the presence of autoantibodies and the degree of metabolic impairment (Sosenko 2006).  
Autoantibody positive subjects enrolled in the DPT -1 study who had impaired or indeterminate 
glucos
e tolerance (ie, a glucose level after ingestion of oral glucose of > 200 mg/dL before 
120 m in, and/or a glucose level at 120min 140-200 mg/dL and/or fasting glucose between 110 and 
126 mg/dL ) were at very high risk (78% over 5 years) of developing T1D over a f ollow- up per iod 
of 5 t o 6 ye ars. Similar results confir ming the very high risk of those with abnormal glucose were 
found in the ENDIT (European Nicotinamide Diabetes Intervention Trial) study in 
which nicotinamide failed to prevent the onset of diabetes in relatives at risk for the disease 
(Gale 2004). The results of the recently completed study, “A nti-C D3 Monoclonal Antibody 
(Teplizumab) for Prevention of Diabetes in Relatives At-R isk for Type 1 Diabetes 
Mellitus” (TrialNet TN-10) confirmed  this high risk: The median time to diagnosis of T1D in 
the high-r isk group with these clinical features was 24.4 months. In the TN-10 study there was 
a decline in the ability to make insulin in the placebo-t reated participants. The mean (standard 
deviation [SD]) decline in the insulin secretory capacity (calculated from a 2-c ompartment 
model 
and adjusted for age and body surface area) was 44061±253 (SD) pmol/ml/120 min 
(n=30).  
2.2. Teplizumab  Overview  
The Fc-engineered teplizumab [hOKT3γ1 (Ala-A la)] was developed as an approach to mitigate 
the adverse effects 
of OKT®3 resulting from Fc/FcR engagement (Keymeulen 2005).  OKT®3 
produce
s profound, transient T -cell depletion in vivo.  It also activates T cells, is strongly 
mitogenic, and its use in vivo is associated with severe cytokine -release syndrome (incidence 
>90%).  The cytokine- release syndrome (CRS)  induced by OKT®3 is characterized by fever,
chills, nausea, vomiting and other symptoms, and usually requires corticosteroid therapy to
suppress.  OKT®3 also is associated with a small incidence of EBV lymphomas (~1% -2%).  T -
cell activation is strongly facilitated by the interaction of Fc component of OKT®3 with Fc
receptors on lymphocytes (Fc/FcR engagement).
Tepli
zumab is a 150- KD humanized mAb that binds the CD3- e epitope of the T cell receptor 
(TCR) complex with affinity equal to OKT®3, but it differs from OKT®3 in two properties: 
1.The humanization process has resulted in the generation of a mAb that used less than 10%
of the original murine amino acids in the antibody construction.  The clinical consequenceof this property is reduced immunogenicity or formation of anti-idiotypic antibodies.
2.Two amino acids have been changed (leucine234 to an alanine and leucine 235 to analanine) in the Fc portion of the immunoglobulin that disrupt Fc receptor and complement
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   12 component C1q binding.  These two amino acid changes were aimed at eliminating the 
majority of cytokine-mediated toxicity observed during infusions of OKT®3.  
The modified F c compone nt of teplizumab minimize s the act ivating capacity of the antibody 
c
ompared with unmodified muri ne OKT®3.  
Teplizumab has been evaluated in a number of clinical trials in the prevention or delay of T1D in 
high risk individuals and in new onset T1D, as well as  in re nal and islet allo- transplantation, and 
psoriatic arthritis. There are ongoing studies evaluating teplizumab in newly-diagnosed pediatric 
patients (Phase 3 PROTECT study, PRV -031- 001) and in combination therapy with a genetically 
modified strain of Lactobacillus designed to secrete human pro-insulin and human interleukin- 10. 
By 
far the most extensive clinical trial experience is in children and adults with newly diagnosed 
T1D, 
where over 1000 individuals in 7 studies have been treated with teplizumab. Results from 
these studies suggest that it is a  promi sing candidate for disease modification of T1D. In pilot and 
proof-of- concept clinical studies conducted in young children, adolescents, and adults, short 
courses
 (approximately 2 weeks) of teplizumab treatment have been shown to be safe and well 
tolerated, resulting in 
relative sparing of β cell function in those who were recently diagnosed 
with T1D (Herold 2002, Herold 2005, Herold 2013a, Herold 2013b). 
A multi- arm, multinational Phase 2/3 study of teplizumab (known as the “Protégé” study) was 
previ
ously conducted by MacroGenics and Eli Lilly and Company. Over 500 children and adults 
8 to 35 years old with T1D were enrolled within 12 weeks of diagnosis and evaluated in 3 
different teplizumab dosing regimens or placebo (Sherry 2011, Hagopian 2013). The study used 
a novel and untested composite primary endpoint integrating glycemic control, measured by 
hemoglobin A1c (HbA1c) level, and insulin use; specifically, participants were considered to 
meet the primary endpoint if they had HbA1c <6.5% and insulin use <0.5 units/kg/day at 1-year 
post randomization. Although the study did not meet this primary endpoint, the study results in 
the randomized treatment group (14-day regimen, 9 mg/m2 dose per course) showed a 
statistically significant benefit in slowing the decline in C-peptide at 18 and 24 months, which 
supported the findings of previous studies that teplizumab does have the ability to preserve β cell 
function in those newly diagnosed with T1D (Hagopian 2013). Furthermore, the effect of 
teplizumab treatment was even more notable in participants  with the following characteristics at 
the time of study entry: enrolled in sites in the United States, 8 to 17 years of age, higher baseline 
C peptide 
levels, and randomized within 6 weeks of TID diagnosis (Hagopian 2013). 
2.2.1. Resul
ts from the TN-10 Study  
The recently completed TN -10 study “ Anti-CD3 mAb (teplizumab) for Prevention of Diabetes in 
Relatives At-R isk for Type 1 Diabetes Mellitus” study (referred to as TN -10 hereafter)  tested 
whether a single 14- day course of treatment with teplizumab would delay the time to diagnosis of 
T1D in relatives of patients with T1D who were at very high risk for the diagnosis based on the 
criteria of at least 2 autoantibodies and dysglycemia during an oral glucose tolerance  test (Herold 
2019). Participants were randomized to a single 14- day course of teplizumab or placebo and 
followed for development of type 1 diabetes using oral glucose tolerance tests performed at 6-
month intervals. Seventy- six participants (55/76 [72%] were less than  18 years  of age ) were 
randomized (44 to teplizumab; 32 to placebo). Median follow -up was 745 days (range 74-2683 
days). The duration of follow up was more than three years in 57 (75%) participants. Type 1 
diabetes was diagnosed in 42 (55%) par ticipants.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   13 The primary endpoint was the time to the diagnosis of T1D, which occurred in 19 (43%) 
teplizumab and 23 (72%) of placebo participants.  The hazard ratio of teplizumab to placebo was 
0.412 (95% CI: 0.216, 0.783, adjusted Cox proportional hazards, p=0.006)  (Figure 1).  The 
annualized rates of diabetes were 14.9% and 35.9% per year, in the teplizumab and placebo arms, respectively.  
Figure 1: Effects of Teplizumab Treatment on Development of Type 1 Diabetes  
Although the primary mechanism of action of the antibody involves binding the CD3 antigen ta rget 
on T
 cells , recent studies have suggested that the mode of action of teplizumab involves induction 
of CD8+
 T cells characterized by the expression of EOMES, TIGIT, and KLRG1. These cells were 
originally identified by a 
RNAseq analysis of peripheral blood cells and confirmed by 
flow cytometry in the clinical responders (Long 2016). In the TN-10 study, an increase in the 
frequency of the TIGIT+KLRG1+ CD8+ T cells (of the CD3+ cells) in the teplizumab-t reated 
subjects at 3 and 6 months after enrollment was observed compared to baseline and  compared to 
placebo treated participants (Figure 2 ). 
Kaplan -Meier estimates of the proportion 
of participants who had not developed 
clinical diabetes in the two study arms. The 
overall hazard ratio was 0.412 (95% CI: 
0.216, 0.783)  (p=0.006, two -sided, Cox 
model). The median time to type 1 diabetes 
was 48.4 months for teplizumab group and  
24.4 months for the placebo group. The 
insert shows the total number of 
participants with and without clinical type 
1 diabetes at the conclusion of the study.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   14 Figure 2: Percentage of KLRG1+TIGIT+CD8+ of total CD3+ T cells in the teplizumab and 
placebo treated participants.  
Studie
s from other clinical settings suggest that these cells have impaired function (i.e. 
“exhaustion”). It is postulated that cells with this ph enotype are unable to cause the autoimmune 
killing of insulin producing beta cells that is the hallmark of the disease. These CD8+ T cells are 
not, however, inactive, since, in the TN -10 study, the few persons with detectable EBV and CMV 
viral DNA showed r apid resolution (see below). The resolution of EBV and CMV activation and 
the absence of an increased rate of infectious adverse events suggest that the duration of functional 
effects of teplizumab on T -cells may be affected by their avidity for auto antigens , viral or other 
antigens.  Subsequent mechanisms involved in the therapeutic effects are incompletely understood. 
2.3. Safety Experience with Teplizumab 
Much of the safety experience with teplizumab are in Stage 3 T1D individuals. I n the Protégé and 
other  clinical studies, teplizumab is generally very well tolerated. In general, there are no major 
diff
erences in overall adverse events (AEs) of clinical concern and serious adverse events (SAEs) 
between teplizumab and placebo groups. The most common AEs assoc iated with teplizumab are 
a decrease in white blood cell counts, nausea and/or vomiting, upper respiratory infections or 
nasopharyngitis and elevations in AST or ALT and anemia, all usually mild or moderate. The most 
frequent observation is a decrease in white blood cell count (WBC), including, in order, transient 
lymphope
nia, leukopenia, and neutropenia. Transient lymphopenia has occurred in ~2/3 of 
teplizumab recipients and 
is usually mild or moderate, which is consistent with 
teplizumab’s mechanism of a ction (Sherry 2011, Hagopian 2013 ). These events are usually 
self-l imited and occur 
with teplizumab dosing and spontaneously reconstitute. For example, 
lymphocytes return to 80% of baseline levels within approximately 14 days of dosing. 
Approximately half of those who receive teplizumab develop a mild rash, sometimes 
pruritic, during dosing cycles, which spontaneously resolves within 7-14 days. Due to its 
mechanism of action, cytokine release syndrome is a potential concern with teplizumab dosing 
but occurs in <10% of teplizumab-t reated individuals (for example ~6% in the Protégé study) 
and is usually mild-t o-moderate and well 
The mean±95% CI are shown. The 
estimates and percent increase between 
the teplizumab vs. placebo groups are (3 months 46.5% (95%CI: 8.23, 98.4%), 6 months 49% (4.13, 113%), 18 months 15.9% ( -14.2%, 56.4%). The 
analysis was performed with log-
transformed values by ANCOVA a nd 
corrected for the baseline values. The 
numbers along the X axis indicate the 
number of samples analyzed.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   15 tolerated. Prophylactic administration of non- steroi dal anti- inflammatory drugs (NSAIDs; eg, 
ibuprofen) and antihistamines (eg, diphenhydramine) appear to reduce the occurrence and the 
severity of its signs and symptoms significantly.  
In the Protégé study, severe AEs were noted in approximately 63% and 30% of teplizumab and 
placebo participants, respectively (Sherry 2011, Hagopian 2013). The most common (though 
occurring in less than 10% of teplizumab treated participants) was decreased white blood cell 
counts
. Three deaths occurred and were evaluated  by the principal investigator in accordance with 
Inter
national Conference on Harmonization (ICH)/Good Clinical Practice (GCP) guidelines. The 
spec
ific causes of deaths and relationship with teplizumab are listed as: (1) “unknown” for which 
the relationship was listed as “none”; (2) “anterior myocardial infarction with ventricular 
tachycar
dia and cardio -respiratory arrest” for which the relationship was listed as “not related”; 
and (3) “
diabetic ketoacidosis” for which the relationship was listed as “unlikely”.  
Despite the decrease in WBC, overall infections were not increased following tepl izumab 
tr
eatment. However, in the Protégé study there were 10 cases of herpes zoster (the result of 
reactivation of varicella zoster virus [VZV], the causative agent of chicken pox and shingles) in 
teplizum
ab-treated patients; all cases resolved without cons equence. In the study, other herpes 
virus infections (eg, 
cytomegalovirus and Epstein-B arr virus) were not increased with teplizumab 
treatment ( Sherry 2011, Hagopian 2013). 
M
ore information i s availabl e in the Investigator’ s Brochur e (IB). 
In the r
ecentl y com pleted TN-10 study, the adv erse events in thos e with S tage 2 disease are shown 
below.  
Grade of adverse events in the TN -10 tria l designated as possibly, probably, or definitely related 
to study drug are shown in T able 1 and adverse events by category related to study drug are shown 
in Tabl e 2.  
Table 1: G rade of adverse events related to s tudy d rug 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   16 Table 2: Adverse events by category and designated and possibly, probably, or definitely 
related to study drug.  
  Adverse Effect Category  Teplizumab  Placebo  
No. of  
Events# No. of  
Participants  (%) No. of  
Events No. of  
Participants  (%) 
Blood/Bone Marrow***  45 33 (75)  2 2 (6.2)  
Dermatology/Skin***  17 16 (36.4)  1 1 (3.1)  
Pain 11 5 (11.4)  5 3 (9.4)  
Infection  8 5 (11.4)  5 3 (9.4)  
Gastrointestinal  5 4 (9.1)  3 3 (9.4)  
Metabolic/Laboratory  7 4 (9.1)  2 2 (6.2)  
Pulmonary/Upper Respiratory  6 4 (9.1)  0 0 (0)  
Constitutional Symptoms  3 2 (4.5)  0 0 (0)  
Allergy/Immunology  2 2 (4.5)  0 0 (0)  
Cardiac General  1 1 (2.3)  1 1 (3.1)  
Endocrine  0 0 (0)  2 2 (6.2)  
Vascular  1 1 (2.3)  1 1 (3.1)  
Neurology  1 1 (2.3)  0 0 (0)  
Ocular/Visual  1 1 (2.3)  0 0 (0)  
Musculoskeletal/Soft Tissue  2 1 (2.3)  0 0 (0)  
Hepatobiliary/Pancreas  0 0 (0)  1 1 (3.1)  
Syndromes  1 1 (2.3)  0 0 (0)  
Hemorrhage/Bleeding  1 1 (2.3)  0 0 (0)  
Total Events and Individuals  112 44 (100)  23 32 (100)  
One individual who was treated with teplizumab, was diagnosed with serum sickness and received 
an abbreviated course of prednisone. This adverse event is captured under “pain”  (of joints) above. 
Similar to previous studies with teplizumab in new onset type 1 diabetes patients, the lymphocyte count declined to a nadir on day 5 by 72.3% ( interquartile range:  82.1, 68.4%)  (p<0.0001) ( Figure  
3). Fifteen (34.1%) of the grade 3 events in the teplizumab group involved lymphopenia during 
the first 30 days after study drug administration. The lymphocyte counts  recovered quickly: 
Lymphopenia resolved in all participants by day 45 except in 1, whose counts returned on day 105.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   17 Figure 3: Absolute lymphocyte counts in the study groups are shown over the first 7 weeks 
after enrollment  
A sp ontane
ously resolving rash, as previously noted, occurred in 36% of teplizumab -treated 
participants. The rates of infection were similar in the two treatment arms.  
Anti-CD3 mAb treatment has been associated with Epstein -Barr virus (EBV) reactivation  (Herol d 
2003, Mach 1992). At entry, 30 participants (39%) (16 teplizumab and 14 placebo) had antibodies 
against EBV. At weeks 3 -6 after study drug treatment, there was quantifiable EBV DNA in whole 
blood in 8 of the seropositive participants – all in the teplizu mab group, one of whom had 
symptoms of pharyngitis, rhinorrhea, and cough on day 38. In these participants, the EBV DNA 
levels were below the level of quantification between day 43 and 134 (average 77 days). At entry, 
17 participants (10 teplizumab and 7 placebo) had antibodies against cytomegalovirus (CMV). One teplizumab participant, who was CMV seropositive, had detectable levels of CMV DNA at day 20 that was undetectable by day 42. 
2.4. Use of Teplizumab in Children  
The majority of new cases of T1D occur in children under the age of 18.  Moreover, given that the duration of diabetes is a significant risk factor for the development of diabet ic complications and 
the clearly recognized difficulty in attaining excellent metabolic control of diabetes during adolescence. Diagnosis of T1D before the age of 20 incurs greater morbidity and loss of life years than when the diagnosis is made in adulthood. In the TN -10 trial, 72% of the participants were 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   18 children. The adverse event experience was not significantly different in adults and children. 
Altogether, more than 470 children have received teplizumab in clinical trials.  
The study procedures, while greater than minimal risk, offers the possibility of benefit due to the 
close monitoring for all participants and the delay in diagnosis of T1D.  Assent of children along 
with consent of their guardians will be obtained , as appropriate, prior to any study procedures.    
Please refer to the Teplizumab IB for further non -clinical and clinical information on the antibody.  
2.5. Benefit/Risk Assessment  
Type 1 diabetes (T1D) is an autoimmune disease that results in a severe metabolic disease of 
glucose dysregulation. T1D is associated with significant short - and long -term complications and 
ear
ly death. Even with the best metabolic control using the most current insulins and glycemic 
moni t
oring devices, these risks are not eliminated. There is an urgent ne ed to develop a disease 
modifying therapy for T1D. 
Clinical studies with teplizumab in T1D have shown that it is effective in preserving beta 
cell function (as measured by C-peptide) and hence endogenous insulin production (Herold 
2019). In the previous Protégé Study, teplizumab resulted in a statistically significant 
preservation of C-peptide, compared to placebo, at 2 years. As described in natural history 
studies, preservation of residual beta cell function (as measured by C-p eptide levels) is 
protective against short-(hypoglycemic episodes) and long-term complications of T1D, 
including retinopathy, nephropathy and other cardiovascular events (Steffes 2003, Sorensen 
2013 , Lachin 2014 , Kuhtreuber 2015). 
The 
main risks of teplizumab consist of transient lymphopenia and transient self-l imited (mild to 
moderate) rash. Cytokine release syndrome is infrequent (~6%) and there is no overall increased 
risk of clinical infection or cancers. 
Given the potential for important benefit in short- and long-term T1D outcom es compared to the 
transient, mild to moderate risks of teplizumab, the prospect of benefit outweighs the risk 
of participating in this study. 
More detailed information about the known and expected 
benefits and risks and 
reasonably expected adverse events of teplizumab may be found in the IB. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   19 3. Objectives  and Endpoints
Objectives  Endpoints  
Primary  
•To evaluate the  safety and tolerability
of teplizumab treatment, administered
intravenously (IV) to participants inthe TN -10 trial who have developed
T1D.•Incidence of treatment -emergent
adverse events (TEAEs), adverseevents of special interest (AESIs), andserious adverse events (SAEs)
Secondary  
•To evaluate the pharmacokinetics
(PK) and immunogenicity ofteplizumab
•To evaluate whether teplizumab
treatment reduces the loss of β cells,
over 78 weeks (18 months), inindividuals with recent diagnosis ofT1D.
•To evaluate key clinical parameters ofdiabetes management, includinginsulin use, hemogl obin A1c (HbA1c),
and clinically important hypoglycemicepisodes over 78 weeks
•To evaluate whether treatment withteplizumab increases the frequency of
exhausted  T cells•Levels of teplizumab in the serum and
anti-drug antibodies
•The area under the time-versus -
concentration curve (AUC) ofC-peptide after a 4 -hour (4h) mixed
meal tolerance test (MMTT), ameasure of endogenous insulinproduction and β cell function, over78 weeks
•HbA1c levels ; insulin use, defined as
a daily average in units per kilogramper day (U/kg/day ); and frequency of
clinically important hypoglycemicepisodes over 78 weeks
•Frequency of CD8+  TIGIT+  KLRG1+
T cells
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   20 4. Study Design
4.1. Overall Design  
The is a single-arm, multicenter, open- label clinical trial. 
Teplizumab -treated and placebo participants in the TN -10 trial who develop clinical type 1 
diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment in 
this open- label  study within one year of clinical T1D diagnosis.  
Number of Participant s: 
Up to 30 participants may be enrolled in this study. 
Treatment  and Study Duration: 
All participants will receive a 12- day course of teplizumab  given through daily IV infusion. 
Participants  will have a screening period of up to 4 week s, a treatment period of  12 days, and a 
follow-up period of up to 78 weeks (18 months ) from the first dose of treatment.  
4.2. Scientific Rationale for Study Design  
It is recognized that participants eligible for this study have undergone further decline in beta cell 
mass and function since their participation in the TN -10 tria l, leading to the need for exogenous 
insulin 
replacement in order to maintain glycemic control. At this juncture, it is critical to preserve 
the remaining beta 
cell function as this leads to better short-term (ie, hypoglycemic episodes) and 
long-t erm outcomes 
including retinopathy, nephropathy and other cardiovascular events ( Steffes 
2003, Sorensen 2013 , Lachin 2014 , Kuhtreuber 2015). Phase 2 and Phase 3 clinical trials with 
teplizumab hav e consistently shown significant preservation of beta cell function as measured by 
C-peptide in patients with newly diagnosed T1D (Hagopian 2013; Herold 2013a; Herold 2013b; 
Herold 2019). Therefore, it is anticipated that the benefit of teplizumab treatment on preservation 
of
 beta cell function may be r ealized in previous par ticipants of the TN -10 study who now have 
devel
oped clinical t ype 1 di abetes.
Between 20%  and 56% of teplizumab treated patients develop anti -drug antibodies that may be 
neut
ralizing antibodies (NAb). These antibodies can be detected within 2 weeks after t he drug has 
been given. They may affect the immunologic effects of additional courses of teplizumab 
trea
tment, but a safety concern has not been identified – second courses of teplizumab did not have 
an increased frequency of adverse events compared to the  first  course. I n this study, the responses 
to teplizumab treatment in participants with and without anti- drug antibodies will be analyzed. The 
time int
erval between the first (under the TN -10 protocol) and second course of teplizumab 
trea
tment in thi s study  (PRV -031- 002) is longer than has previously been tested and therefore, the 
eff
ect of anti -drug antibodies is not known. Thus, these study participants are different from those 
who previously have received two courses of teplizumab. As eligible and consenting placebo 
partic
ipants in the TN -10 trial will also be treated with teplizumab upon the diagnosis of clinical 
T1D, 
the immunologic effects of teplizumab in the placebo group, who will receive teplizumab 
for the first time, will serve as a comparator to  individuals previously treated with teplizumab. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   21 4.3. Justification for Dose  
In previous clinical studies of teplizumab in T1D, a number of dosing regimens have been 
eval
uated that have included children and/or adults. These studies have evaluated single multi -day 
courses of teplizumab and 2 multi -day courses either 6 or 12 months apart. Although the goals, 
sta
ge of T1D, and entry criteria differed between these studies, all have shown that teplizumab was 
well
 tolerated with an acceptable safety profile, and an ability  to pr eserve  β cell function  and 
improve clinical outcomes in study populations or specific sub-populations. It is these effects that 
support further evaluation and clinical development of teplizumab as a first-i n-class therapy for 
children and adolescents newly diagnosed with T1D (Herold 2002, Sherry 2011, Hagopian 2013, 
Herold 2005, Herold 2013a, Herold 2013b).  
Of 
note, the 14-day regimen evaluated in Protégé (and other previous studies  including the TN -10 
T
he most extensive and detailed e valuation of teplizumab in T1D is from the Phase 2/3 “Protégé” 
study in which 2 multi -day c ourses of teplizumab were given 6 months apart in children and adults 
8 to 35 yea
rs old who were diagnosed with T1D within 12 weeks of T1D diagnosis. In that study, 
three dosing regimens of teplizumab were evaluated and included: (1) a 14- day course with a 
c
umul
ative dose of 9.0 mg/  m2; (2) a 14 -da y course with a cumulative dose of 3.0 mg/  m2; and (3) 
a 6-day course with a cumulative dose of 2.4 mg/  m2. I n the open- label Phase 2 segment of Protégé, 
participants received the 14- da y regimen of 9.0 mg/m2/course at enrollment and 26 weeks later to 
as
sess safety and tolerability before the double -blind study was started. The Phase 3 segment 
studi
ed the three teplizumab dosing regimens in comparison to placebo. The open label Phase 2 
segm
ent of Protégé enrolled 38 participants, and the randomized, double -bli nd Phase 3 segment 
enrolled 207, 102, and 106 teplizumab-treated participants, respectively, and the placebo arm 
98 participants ( Sherry 2011, Hagopian 2013 ).  
In addition to assessments of safety and efficacy, the Protégé study conducted extensive PK and 
immunogenicity evaluations. From this data, a detailed population PK model has been developed 
using a two- compartment ( pe ripheral and central) model with saturable binding kinetics 
incor
porating body surface area (BSA), proportional dosing, and teplizumab AUC, trough 
concentration,  and peak concent ration.  These findings showed that PK was independent of age, 
gender, race, region, disease state or onset, although it was influenced by antidrug- antibody 
response. 
As described earlier, although the previously untested and unevaluated composite primary 
endpoint
 was not met in the entire study population of Protégé, a positive ef fec t of teplizumab in 
T1D 
was confirmed in Protégé subpopulations, supporting findings from a number of previous 
clinic
al studies. Specifically, participants from certain regions (eg, the United States) who were 8 -
17 years old, who had teplizumab initiated within 6 weeks of T1D diagnosis and with higher C -
pepti
de levels at study entry showed significant retention of endogenous insulin production 
through 2 years compared to placebo treated participants. 
A 14- day course necessitates participants and their par ents or guardians (required by pediatric 
participants) to be available every day for 2 entire consecutive weeks and associated weekends. 
Thi
s requirement is seen to be particularly challenging to children and adolescents and their 
fam
ilies due to work and school obligations and therefore may have a negative influence on 
rec
ruitment and retention as well as a significant bias in a pivotal study.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   22 With the realization of the potential negative impact on many aspects of the clinical trial of a 14 -
day treatment  course combined with the significant experience with teplizumab, in this study we 
propose to use a regimen that is more acceptable to participants and their families  that deliver s 
clinically overlapping exposures that could support approval for teplizumab. 
We propose to modify the dosing regimen to 12 days: Day 1: 106 µg/m2, Day 2: 425 µg/  m2, and 
Days 3 -12: 850 µg/  m2/day. During the first 2 days of ramp- up, approximately 5.9% of the total 
dose is given. In the last 10 days, ~94% of the total dose is delivered in equally divided doses.  Compared to a 14- day dosing regimen, this study’s 12- day teplizumab course has a modified 2 -
day ramp -up phase but also has a 10- day fixed- , maximal dosing period like the 14- day course. 
Based on calculations, the amount of teplizumab given in the 12 - and 14- day approach only differs 
by 0.005 mg/m
2. But due to practical aspects of rounding and calculating the BSA and a given 
dose, these courses are co nsidered clinically equivalent.  
As shown in the PK simulatio ns in Figure 4, the firs t 2 doses in the 14 -day regimen are calculated 
to have very low, almost negligible, serum concentrations with serum concentrations of the last 11 
doses of both regimens that are superimposable. In both instances, >90% of the total dose per 
course is given in the final 10 days in similar equally divided doses (0.850 mg/m2 in the 12-day 
course versus 0.826 mg/m2 in the 14- day course). The first 2 days of the 14- day course delivers a 
nominal amount (ie <2.0%) of the course’s total dose. The final trough concentrations (426±220 ng/mL [14- day regimen] and 435±225 ng/mL [12- day regimen]), as we ll as the elimination times 
are overlapping in both regimens.  
Figure 4: PK Simulation of 12 -Day and 14-Day Dosing Regimens 
Taken
 together, this study will evaluate a more participant and family -friendly approach to deliver 
the same dose of 9.0 mg/m2 of teplizumab  over a course of 12 days, which has been shown to be 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   23 well tolerated, safe and effective in preserving β cell function. Because of the similarities and 
overlap of the regimens and exposures, data from this study can be combined with data from other studies to support the application and approval for teplizumab as a disease modifying therapy for the study population in those recently diagnosed with T1D. 
4.4. End of Study  Definition  
A participant is considered to have completed the study if he/she has completed all phases of the 
study including the last visit shown in the Schedule of Events (Section 1.3). 
The end of the study is defined as the date of the last visit of the last participant in the study.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   24 5. Study Population
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria are met : 
1. Previous participant in the TN-10 study.
2.Participant has received a diagnosis of T1D after the conclusion of the TN -10 study,
according to the criteria from the American Diabetes Association  (ADA) .
3.Participant is able  to initiate teplizumab treatment required in this study within 1 year of
T1D diagnosis.
4.If participant is female with reproductive potential, she must have a negative pregnancytest prior to enrollment and be willing to avoid pregnancy for at least 18 months from the
first dose of study drug.
5.Participant is w illing and medically able to postpone live vaccine immunizations for 1 year
after receiving the last dose of study drug in this study.
6.Participant is w illing to forego other forms of experimental treatment during the entire
study.
7.Participant  and/or guardian has given  informed consent and  assent  as applicable.
5.2. Exclusion Criteria 
Participants will be excluded from the study if any of the following criteria is met at screening or 
before the first dose is given:  
1. Lymphopenia (< 1000 lymphocytes/µL)
2. Neutropenia (< 1500 polymorphonuclear cells [ PMNs] /µL)
3. Thrombocytopenia (< 150,000 pla telets/µL)
4.Anemia ( hemoglobin < 10 g/dL)
5.Aspartate aminotransferase ( AST ) or alanine aminotransferase ( ALT ) >1.5 x upper limit
of normal ( ULN )
6.Total bilirubin >1.5 x ULN . Exception: participant s with the diagnosis of Gilbert’s
syndrome may be eligible if  they have no other causes leading to hyperbilirubinemia.
7.Chronic active infection except  localized skin infections. This may be discussed with
the Medical Monitor on a case by case basis.
8. Participant has any of the following regarding tuberculosis (TB):
•A history of latent or active TB
•Signs and/or symptoms of TB
•Recent close contact with a person with known or suspected active TB, unless
appropriate isoniazid prophylaxis for tuberculosis was given
•A history of a chest X -ray consistent with  active TB or ol d, inactive TB,
•A history of a positive purified protein derivative  (PPD)  skin test result (>10 mm
induration)
•At screening is positive or repeatedly indeterminate with an approved interferon-
gamma release assay (IGRA; eg, QuantiFERON -TB test)  or PPD.
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   25 •If required by local, regional or national regulations, a recent (within 3 months)
chest X -ray or one conducted at screening read by a qualified radiologist consistent
with current, active TB or old, inactive TB
9.Vaccination with a live virus within 8 weeks before first dose of the study drug
10.Vaccination with a killed virus within 4 weeks before first dose of the study drug
11. A history of infectious mononucleosis within the 3 months before  screening .
12. Laboratory or clinical evidence of acute infection with EBV or CMV.
13.Serological evidence of current or past human immunodeficiency virus ( HIV), hepatitis
B virus (HBV) or hepatitis C  virus (HCV) infection.
14. C urrently pregnant or lactating or  planned pregnan cy within 18 months 2 years after
receiving the last dose of the study drug
15. Chronic use of steroids or other immunosuppressive agents.16. A history of asthma or atopic disease requiring chronic cortico steroid treatment.
17. Untreated hypothyroidism or active Graves’ disease.18.Current use of non- insulin pharmaceuticals or dietary supplements that may affect
glycemic control.
19.Participation in any therapeutic drug or vaccine clinical trial w ithin 12 weeks before the
first dose of study drug.
20.Any condition that, in the opinion of the investigator, would interfere with the studyconduct or the safety of the participant .
5.3. Enrollment
Potential study participant s will be identified through previous participation in the TN -10 trial. 
TN-10 participants , regardless of whether they received teplizumab or placebo in that study, are 
invited and screened for this study if they have been diagnosed with T1D  and can receive 
teplizumab within 12 months of the diagnosis. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   26 6. Study Drug Dosing
6.1. Study Drug  Administered  
All participants  will receive an IV infusion of teplizumab  once daily for 12 consecutive days. 
The participant’s body surface area ( BSA ) will be calculated by  the study pharmacist using the 
Mosteller formula. The BSA will be calculated on Study Day 1 and will be based on the 
participant’s height and weight on that day. This calculation will be used for the doses given over 
the entire 12- day treatment course . For dosing purposes, the participant’s BSA should be rounded 
up to the nearest tenth place regardless of the number in the hundredth position. For example, if 
the BSA is 1.61 m2, it will be rounded up to 1.7 m2; if the BSA is 1.67 m2, it will also be rounded 
up to 1.7 m2. The dose should be rounded to the nearest whole number.   
The drug dosing is: 
Day 1: 106 µg/m2 
Day 2: 425 µg/m2 
Days 3-12: 850 µg/m2 daily  
Total per course: 9.0 mg/m2 
The Mosteller formula  is as follows:  
BSA (m²) = ([Height(cm) x Weight(kg)]/ 3600)½ 
Teplizumab is administered via an IV infusion over a minimum of 30 minutes in the research or 
hospital setting. The daily time of the infusion should be consistent but may be adjusted by a time 
window of ±4 hours on each day. If there are signs or symptoms  of infusion reaction during the 
60-minute observation period, the participant should be observed for an addition al 60 minutes or
until the reaction resolves, whichever is longer.
6.2. Preparation/Handling/Storage/Accountability  
The formulation of teplizumab consists of 10 mM sodium phosphate, 150 mM sodium chloride, 
and 0.05 mg/mL Tween 80, with pH 6.1.  
Final drug product will be provided at a concentration of 1 mg/mL for a total of 2 mg of recoverable drug product per vial. 
The vials should be stored upright at 2° –8°C and must not be frozen or shaken. Because there is 
no preservative and drug loss occur  over time, administration of the study drug should begin as 
soon as possible and no later than 2 hours after preparation. The drug may be prepared into a bag 
for infusion and delivered by gravity or by infusion pump. Intravenous drug delivery devices, 
including IV bags and tubing, must be composed of polyvinyl chloride ( PVC ). Refer to Pharmacy 
manual for details.  
Laboratory studies that will be obtained prior to each dose are described in the Schedule of Events 
(Section 1.3) and Appendix 2 (Section 10.2). The same-day results of chemistries (including liver 
function tests  [LFTs]), WBC  counts, hemoglobin, hematocrits  and platelets must be reviewed prior 
to commencement of the drug infusion on each dosing day. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   27 6.3. Concomitant Therapy  
6.3.1. Diabetes Management and Insulin Use  
All participants should receive intensive diabetes management of their T1D using approved 
therapies according  to the recommendations of ADA to achieve glucose levels that appear to 
decrease some of the short -term and long- term sequelae of T1D. Currently the glycemic targets by 
the ADA are focused at management strategies to achieve an HbA1c level of <7.5% (58 
mmo l/mol) for individuals 17 years old and younger and <7.0% (53 mmol/mol) for those 18 years 
and older , while minimizing severe or frequent hypoglycemic events. If there are local, regional, 
or national recommendations to be followed that supersede ADA recommendations, these glycemic control targets (ie, HbA1c or glucose levels) should not be more liberal (ie, higher) than the ADA recommendations. The Investigator will document , in the case report form ( CRF ) and/or 
the source documents, the glycemic goals and  the guidelines being followed.  
The glycemic goal should be attempted through proper glycemic monitoring, administration of exogenous insulin, and monitoring of activity level and diet. Exogenous insulin may include rapid, 
intermediate, and/or long -acting  insulins, administered intermittently or via the use of a personal 
insulin pump. Blood glucose levels should be measured at least 4 times a day, including before 
meals and before bedtime. Approaches to achieve these HbA1c goals will be the responsibility of the participant, their caregivers, and their healthcare providers.  
Insulin use, including the type of products, dosages, and dosing schedules, is expected to change 
during the course of the study. As part of routine T1D clinical care, if the caring physician judges 
it to be clinically appropriate, a participant’s insulin dose may be increased, reduced, or even 
discontinued.  
Insulin Discontinuation  
If a participant has achieved a HbA1c level of ≤6.5% with insulin use of ≤0.25 U/kg/day, insulin 
therapy c an be discontinued. The participant’s blood glucose and HbA1c levels should continue 
to be monitored per protocol, and urine ketones should be tested at home once a day. During 
routine blood glucose monitoring, if the participant’s blood glucose level exceeds 200 mg/dL and/or urine ketone level is moderate or greater, the participant should consult with their primary 
physician and/or the clinical site staff for further evaluation. If the fasting blood glucose exceeds 
126 mg/dL or HbA1c exceeds 6.5%, as documented by repeat testing, the resumption of insulin 
therapy should be considered. 
6.3.2. Prophylactic Medications  
Ibuprofen and antihistamine will be administered prophylactically prior to teplizumab infusion on 
the first 5 days of treatment. After Day 5, the use  of pre -medication is optional.  If ibuprofen is 
contraindicated, acetaminophen should be given instead. Further dosing of ibuprofen, 
antihistamines, and/or acetaminophen can be used as needed for fever, malaise, headache, arthralgia, or rash. All prophyla ctic medications administered should be recorded on the 
concomitant medication CRF.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   28 6.3.3. Prohibited Medications  
Participants will be instructed not to use steroids, (eg, prednisone [ topical or systemic ]), other 
immunosuppressive agents, or chronic inhaled or nasal corticosteroids during this trial in order to 
reduce infectious risks and to prevent possible impact on diabetes  outcome. A short course (ie, 
approximately 2 weeks or less) of systemic (including oral, inhaled or parenteral) corticosteroids may be used for treatment of a transient condition. In the event of a medical condition requiring 
glucocorticoid treatment, they may be used after discussion with the Medical Monitor. However, 
no individual will be withdrawn from analysis if this occurs. 
Participants will be instructed not to receive live vaccinations for 1 year after dosing.  In addition, 
participants should not receive vaccination with a killed virus vaccine within  8 weeks after the last 
dose of the study drug, unless this is approved by the Medical Monitor.  
6.3.4. Emergency Precautions  
Before every  infusion of study drug, appropriate emergency equipment and trained personnel 
should be present. At a minimum, the following will be available: 
• Epinephrine 1 mg doses (or resuscitation dose recommended by local, regional or national
authorities) for IV injection
• Dexamethasone 10 mg (or equivalent glucocorticoid) for IV injection
• Diphenhydramine: 50 mg (or equivalent antihistamine) for IV injection
• Resuscitation equipment and other supplies for the emergency management of anallergic/toxic reaction.
If AEs develop during infusion, the infusion may be slowed or interrupted, as determined by the 
Investigator. If interrupted, the infusion may be restarted, preferably at a slower rate, if deemed 
reasonabl e by the Investigator. Any changes in the infusion rate must be recorded with the reason 
for the change. In any cases of AEs determined or suspected to be related to the infusion of the study drug, the participant should be treated using appropriate medica l practices and procedures.  
During or after the infusion of study drug, if a participant experiences any of the following signs, the participant will be observed, and the severity of the reaction will be evaluated:  
• Fever of >38.5°C (101.3°F)
• Rigors or myalgias
• Pain, swelling, or edema near the infusion site
• Local or systemic rash
• Mucosal congestion or edema
• Significant (eg, 30%) drop in systolic or diastolic blood pressure or increase in resting heart
rate
• Hyperventilation, wheezing or difficulty breathing
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   29 • Change in mental status
Acetaminophen (or similar drug) and/or additional NSAID may be given if needed, glucocorticoid 
treatment may be considered . The participant should be treated using appropriate medical practices 
and procedures. The participant will be continuously monitored until their clinical status returns to baseline or is significantly improved. 
If an infusion is discontinued, an estimate on the volume of the infusion given and a quantitative 
assessment of the remaining volume should be documented. 
The Medical Monitor should be notified of all cases of actual or suspected infusion reactions and 
AEs thought to be related to the study drug infusion. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   30 7. Interruption or Discontinuation of Study Drug Treatment  and
Participant Discontinuation/Withdrawal
A participant will not be automatically withdrawn from the study if they temporarily or 
permanently discontinue study drug before the end of the treatment course. If a participant 
permanently discontinues study drug for any reason,  they should be encouraged to return for the 
Early Termination  visit.  
Unless lost to follow -up, SAEs  must be reported for participants who withdraw early from the 
study for one year after their last study drug dose (Section  8.4.1).   
7.1. Interruption of Study Drug Treatment  
Blood samples will be drawn for c linical laboratory tests, as listed in Section 1.3, and the results 
will be reviewed by the Investigator before the study drug can be administered on each day of the 
treatment . 
Study drug dosing may be interrupted temporarily, for an individual participant, if any of the following medically important events occur:   
• A significant infection, defined as:
-Any severe infection meeting SAE criteria (Section  10.3.2), or
-Any clinically significant infection not meeting SAE criteria but per Investigator’s
judgment might put the participant at risk, or
• An SAE , a study drug- related severe AE, or an AE  that puts a participant at risk , defined
as:
-Any SAE or
-Any severe AE that is considered related (possibly, probably, or very likely related) to
study drug (as defined in Section  10.3.1) , including but not limited to an infusion
reaction categorized as a severe or SAE by the Investigator.
-Any AE (including mild or moderate) of any relatedness to study drug that  leads to  the
Investigator to believe that further dosing of study drug during that course puts the
participant at undue risk.
• If any of the following out-of- range lab results is observed (normal range per local lab
reference ranges), the test may be repeated on the same day. If the repeated test result
normalizes, that day's dose may be given. If the value is still in the indicated range orworsens, or if the test cannot be repeated on the same day, that day's dose should be
withheld.
-ALT and/or AST >3  x ULN but ≤5 x ULN
-Total bilirubin >2  x ULN but ≤3 x ULN
-Platelet count >50,000 but ≤100,000
-Hemoglobin >8.5 g/dL but ≤10 g/dL
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   31 Note: When clinical and laboratory abnormalities are considered related to T1D disease activity 
(ie, hypoglycemia and hyperglycemia) and study drug is not considered a contributing factor, 
administration may not need to be modified. The site Investigator should consult with t he Sponsor 
if this is encountered.  
If the above events resolve within 2 days, study drug dosing may be resumed according to the 
original schedule. The treatment course will not be extended beyond 12 days. 
If the above events do not resolve after 2 consecutive days of interruption, the Medical Monitor 
must be consulted regarding continuation of study drug dosing. 
7.2. Discontinuation of Study Drug Treatmen t 
The study drug should be discontinued permanently if any of the following events occur: 
• The Investigator believes that for safety or tolerability reasons it is in the best interest of
the participant to discontinue study drug.
• A female participant becomes pregnant. Note: The “Pregnancy Report Form” should be
submitted for all pregnancies that occur in a study participant. Pregnancy should befollowed for outcome and any premature terminations reported. The health status of themother and child including date of delivery and the child’s sex and weight should bereported after delivery.
• A severe in fection requiring inpatient hospitalization or repeated doses of parenteral
antibiotics
• A severe hypersensitivity reaction, such as anaphylaxis or angioedema with or withoutrequiring hemodynamic support (ie, epinephrine and/or blood pressure medications) or
mechanical ventilation, to the study drug or an infusion reaction (including cytokine releasesyndrome) with signs or symptoms categorized as an SAE.
• The participant has a clinically significant cardiovascular event.
• The participant is diagnosed with a  malignancy, lymphoma or a lymphoproliferative
disorder.
• If any of the following lab values is observed (normal range per local lab standard), thenext study drug dose should be held until a repeat test is obtained and evaluated. If the out -
of-range result  is confirmed on two consecutive dosing days, the participant should be
discontinued from any further study drug treatment.
-ALT  and/or AST > 5X ULN
-Total Bilirubin > 3X ULN
-ALT and/or AST >3 X ULN AND Total Bilirubin >2 X ULN (Hy’s Law criteria)
-Platelet count < 50,000/µL
-Neutrophil count <500 cells /µL
-Hemoglobin of <8.5 g/dL
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   32 • Any ≥Grade 3 AE during dosing other than:
-Lymphopenia
-Neutropenia
-Low total WBC
-Hypoglycemia or symptoms and signs of a hypoglycemic episode
-Hyperglycemia or symptoms and signs related to hyperglycemia
-Fatigue or malaise
-Insomnia
-Cheilitis
-Dry skin
-Nail changes
-Hot flushes or flashes
-Headache
-Myalgia
-Flu-like syndrome
• Any medically important event such as a concurrent illness, complications, or abnormal
laboratory result that, in the opinion of the Investigator, contraindicates continued dosing
of the participant
• Administration of prohibited medication or dose modification of concomitant medicationsthat necessitate discontinuation of study drug administration
• A general lack of compliance with study visits and procedures per study team or a miss ing
3 consecutive study drug administrations
The Study Medical Monitor must be notified within 24 hours of any participant who is permanently 
discontinued from study drug dosing. Participants who have study drug dosing permanently 
discontinued will be encouraged to receive follow -up care and evaluation as scheduled, unless 
consent for follow -up is withdrawn. 
7.3. Participant Discontinuation/Withdrawal from the Study  
A participant will be withdrawn from the study for any of the following reasons: 
• Lost to follow-up
• Withdrawal of consent/assent
• Death
• Study I nvestigator or Sponsor, for any reason, decides the participant should be withdrawn
from the study.
• Pregnancy (see Section 8.4.5)
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   33 When a participant withdraws before completing the study, the Sponsor is to be notified and the 
reason for withdrawal is to be documented.  
If a participant withdraws from the study before the end of study, all attempts should be made to 
obtain Early Termination  assessments.  
7.4. Lost to Follow -up 
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. 
If a participant is lost to follow -up, every reasonable effort must be made by the study- site 
personnel to contact the participant and determine the reason for discontinuation/withdrawal. The 
measures taken to follow -up must be documented. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   34 8. Study A ssessments and Procedures
The assessments and procedures required in this study are listed in the Schedule of Events table in 
Section  1.3.  
It is recognized that the amount of blood that may be drawn for research purposes in children and 
adults may not exceed certain limits, both at a single visit and over a set time  period. In  any 
participant whose clinical condition might be adversely affected by removal of the blood volumes stated  in this protocol , for example, a participant with significant anemia or compromised cardiac 
output, Investigators should consider further limiting the volume of blood withdrawn for research purposes. In instances of medical need, it is the responsibility of the Investigator and/or 
participant’s healthcare providers to determine if blood draws in excess of the protocol- stated 
volumes should occur. Because blood sampling in excess of those mandated by the protocol may 
be taken in the course of providing care during this study, sites must ensure that all instances of blood collection in excess of permitted volumes are recorded and justified in the partic ipant’s 
record.  
Additional blood volumes may be collected by individual sites and will be included in the site -
specific informed consent form. 
8.1. Screening and Baseline Assessments 
8.1.1. Screening  (Visit -1) 
This study will enroll former participants of the TN -10 protocol who have developed T1D within 
the past 12 months.  
The participant/parent/guardian will be asked to sign an informed consent  and/or assent  describing 
the purpose, risks, and benefits of screening for the trial. A participant /parent/guardian ’s signature 
indicates that he/she understands the potential risks and benefits of study participation. During the 
screening visit, clinical tests will be performed to determine eligibility, as described in the 
Schedule of Events (Section 1.3).  
Any participant either not eligible or not willing to be enrolled into this study is eligible for 
continued follow -up as part of the Long- Term Investigative Follo w-Up in TrialNet Study (LIFT, 
TN-16).  
8.1.2. Baseline Assessments and Initiation of Teplizumab Treatment  (Visit 1) 
Participants  will undergo a  4-hour mixed meal tolerance test ( 4h MMTT)  and other baseline 
clinical tests  at Visit 1 , as indicated in the Schedule of Events (Section 1.3). All relevant laboratory 
and clinical data will be reviewed to confirm eligibility  and document baseline val ues. 
Subsequently, eligible  participants will receive the first dose of teplizumab IV infusion  at the same 
visit.  
8.2. Post-Baseline Visits  
Participants will complete a 12 -day course of teplizumab treatment and return to the study site for 
follow- up assessments through Week 78, as outlined in the Schedule of Events (Section 1.3). 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   35 Participants who discontinue the study before the final visit at Week 78 should undergo the 
assessments listed for the Early Termination (ET) visit.  
8.3. Efficacy Assessments 
During the study period, all participants will be close ly monitor ed for T1D control, insulin use , 
AEs and laboratory abnormalities , undergo 4- hour MMTT  every 6 months, and provide blood 
samples  for analyses .  
8.3.1. Metabolic Assessments  
A 4h- MMTT  wi ll be performed at study entry (Visit 1) and every 6 months. At each study visit, 
the amount of exogenous insulin that is being taken over the 3 days prior to the visit will be 
docume
nted. HbA1c levels will be measured prior to study drug administration and at each of the 
designated study visits. 
8.3.1.1. H ypoglycemia 
Instances of  significant impairment consistent with hypogl ycemia and r equiring  assistance (ie, 
often referred to as “severe” hypoglycemia),  even in the absence of a blood glucose reading, a re 
classified
 as “Level 3 Hypoglycemia” (IHSG 2017) . Level 3 hypoglycemia may include 
cognit
ive impartment, altered/loss of consciousness, confusion, seizure, syncope/fainting, or 
coma, and support may be general assistance, glucagon, or oral carbohydrate (ie, fruit juice or 
glucose tablets). Such episodes may or may not require medical attention  or hos pitalization.  
This s tudy will consider c linic ally significant hypoglycemia to be Level  3 or greater 
hypoglycemia as de fined below. 
For AE reporting purpose, the severity of a hypog lycemia event  should be identified by the 
Investigator  and c lassified according to CTCAE v5.0 as fol lows: 
•Grade
 3 hypoglycemia: 30-39 mg/dL (1.7–2.1 mmol/L). This is considered severe or
medically significant but not immediately life -threatening. Hospitalization or
prolongation of hospitalization is likely indic ated. It is considered disabling and limits
self-care.
•Grade 4 hypoglycemia: ≤29 mg/dL (1.6 mmol/L). This is considered life threatening (eg,
seizures) with urgent intervention indicated.
•Grade 5 hypoglycemia: Hypoglycemia resulting in death.
8.3.2. Mechanistic Outcome Assessments  
Immune and gene- expression tests  to further understand mechanisms that may be underlying the 
T1D disease process and response to therapy  will be conducted. For this purpose, plasma and 
serum samples for the analyses of peripheral blood mononuclear cells ( PBMCs) , DNA, RNA, will 
be obtained at designated time  points , and serum samples will be  obtained during the MMTT . 
Planned m echanistic studies  include but are not limited to the following: 
1.Immune cell phenotyping by flow cytometry: The markers that will be measured include
those analyzed in the original TN -10 study and other markers that are suggested by
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   36 transcriptomic or other studies. Measurement of cell proliferation will be performed by 
staining with Ki67. The analysis will be done on PBMC s that will be frozen after collection 
and analyzed at a later time. Samples will be collected prior to the first dose of teplizumab and at the indicated intervals afterwards. In participants who receive d their first course of 
teplizumab during the TN -10 study, t he results will be compared to the data from the first 
course of teplizumab administration.   
2. The transcriptional signature of changes in immune cell s with teplizumab treatment by 
single cell RNAseq or similar technologies : These changes will be compared to the findings 
from the previous administration of teplizumab in those who are receiving the drug for a second time.  
3. The frequency and changes in phenotypes of diabetes antigen specific T cells : The 
frequency of these cells will be measured by Class I and/or Class II major 
histocompatibility complex ( MHC ) tetramer and T cell libraries. Frozen PBMCs will be 
used for this analysis.  
4. Metabolic function including glucose tolerance, patterns and magnitude of endogenous cell responses, and other markers of β  cell stress and death.   
5. Analysis of changes in peripheral blood cells : The results of the CBC and differential tests 
will be used.  
6. Anti-drug antibodies  and effects of these antibodies on responses to teplizumab: The titers 
of anti -drug antibodies and presence of neutralizing antibodies will be measured in samples 
collected before and after teplizumab  administration . The presence or absence of these 
antibodies and the changes in immune cells will be analyzed.  
7. Epigenomic analysis of immune cell subsets : This analysis may involve techniques such 
as ATACseq will be performed on frozen cells and will be conducted after the initial 
transcriptomic studies.  
8.4. Safety Assessments  
Safety assessments include clinical safety laboratory tests, AE assessments, and pregnancy 
monitoring. Planned time points for all safety assessments are listed  in Section 1.3. 
8.4.1. Adverse Events and Serious Adverse Events  
See Appendix 3 for the definitions of AEs, SAEs, and reporting instructions.  
AEs will be reported by the participant or, when appropriate, by a caregiver, surrogate, or the 
participant's guardian or legally authorized representative.  
Throughout the study, the investigator must record all AEs, including assessment of relatedness 
and severity (according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events [CTCAE ]). The investigator should treat participants with AE s appropriately and 
observe them at suitable intervals until the events resolve or stabilize.  
8.4.1.1. Time  Period and Frequency for Collecting AE and SAE Information 
All AEs will be collected from the signing of the informed consent form (ICF)  until the follow -up 
visit at the time points specified in Section  1.3. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   37 All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated i n Appendix 3 in Section  10.3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or  SAE after conclusion of the study 
participation . However, if the investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the investigator must promptly notify the 
sponsor. 
8.4.1.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 in Section  10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences . 
8.4.1.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All AEs, SAEs, and AEs of special interest ( AESI, as defined in 
Section 10.3.3) , will be followed until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow -up (as defined in Section 7.4). Further information on follow -up 
procedures is provided in Appendix 3 in Section  10.3. 
8.4.1.4. Regulatory Reporting Requirements for SAEs  
Prompt notification by the investigator to the sponsor of a n SAE is essential so that legal and 
regulatory obligations and ethical responsibilities towards the safety of participants and the safety 
of a study intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other regulat ory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country- specific regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) , 
and investigators. 
For all studies , investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory requirements and sponsor policy and 
forwarded to investigat ors as necessary.  
8.4.2. Clinical Safety Laboratory Assessments 
See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be performed.  
The investigator should report any clinically relevant changes during the study as AEs . Clinically 
significant abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by the investigator to be more severe than expected for the participant's 
condition. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   38 8.4.3. Physical Examinations 
A complete physical exam includes evaluation of general appearance, head, eyes, ears, nose, and 
throat evaluation, neck palpation for thyroid, lymphadenopathy and tenderness, auscultation of the 
heart, lungs and abdomen, palpation of abdomen, evaluation of extremities and skin, and gross neurologic evaluation of strength, sensation and balance. 
A partial physical examination includes general appearance, head, eyes, and throat evaluation, 
neck palpation for thyroid, lymphadenopathy and tenderness, auscultation of the heart, lungs and abdomen, palpation of abdomen, evaluation of extremities and skin. 
Weight and height will be measured using calibrated scales. At each measurement, participants  
will be instructed to remove shoes and outdoor apparel and gear. Details on how to conduct these 
measurements will be provided to sites.   
8.4.4. Vital Signs  and Infusion Reaction Monitoring  
The following vital signs will be measured at time points indicated in the Schedule of Events  
(Section 1.3): 
• Temperature  
• Pulse/heart rate  
• Respiratory rate  
• Blood pressure 
Blood pressure and pulse/heart rate measurements should be preceded by at least 5 minutes of rest in a quiet setting without distractions (eg, television, cell phones).  
On dosing days , vital signs should be measured at pre-dose and at  approximately 15 minutes  after 
the start of the infusion , at the  end of infusion (approximately 30 minutes) , and at 60 minutes  after 
the end of the infusion.  
Participants are t o be monitored for signs or symptoms of infusion reactions. These include but are 
not limited to fever, chills, headache, nausea, vomiting, infusion- site pain , anaphylaxis, wheezing, 
dyspnea, urticaria, and hypotension. If there are signs or symptoms of infusion reaction in a 
participant during the 60- minute post -infusion observation period, the participant should have vital  
signs assessed and continue to be observed until the reaction is resolved.  
8.4.5.  Pregnancy  
Pregnant and lactating women will not be included in the study. Females  of childbearing potential 
must have a negative pregnancy test prior to enrolling in the study and will be required to use a 
reliable and effective form of birth control during the study. Male participants will also be required 
to prevent pregnancy in their partners.  At every study visit the sexual activity of participants of 
reproductive age will be re- assessed.  If a participant who was previously sexually inactive 
becomes sexually active, s/he will be counseled about the need to use a reliable and effective form 
of birth control .  Female participants of childbearing potential will also be required to undergo 
urine pregnancy tests at regular intervals including prior to teplizumab administration. A positive 
pregnancy test will result in withholding scheduled drug infusion, and if confirmed, lead to study 
drug discontinuation. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   39 All pregnancies that are identified during the study must be followed to its termination or delivery,  
and the outcome of each pregnancy must be reported.  The investigator should be informed 
immediately of any  pregnancy whether occurring in a female participant or the female partner of 
a male participant.  The investigator should report all pregnancies within the same time  frame (24 
hours) as SAEs, using the Pregnancy  report form.   
8.5. Pharmacokinetics and Immunog enicity  
Blood samples will be obtained to measure teplizumab  trough level s and anti -drug antibodies at 
time points indicated in Section 1.3. Instructions for sample processing, handling, and shipping 
will be described in the Laboratory Manual.  
8.6. Pharmacodynamics  
Pharmacodynamic parameters are not evaluated in this study. 
8.7. Genetics  
Genetic information about TN-10 participants has already been obtained. There are no additional 
genetic studies planned.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   40 9. Statistical Considerations  
9.1. Statistical Hypotheses  
There is no formal hypothesis to be tested in this study, whose primary objective is to evaluate the 
safety  of teplizumab administration in participa nts of the TN -10 study who have developed clinical  
T1D. For the secondary endpoints, it is proposed that teplizumab treatment will reduce the loss of 
beta cell function (as measured by C -peptide) and will increase the frequency  of exhausted T cells, 
TIGIT+KLRG1+CD8+ T cells , compared to  baseline (at the start o f study drug administration).  
9.2. Sample Size Determination  
The sample size will include a maximum of 33 participants who were free of clinical T1D at the 
conclusion of the TN- 10 study.  
9.3. Populations for Analyses  
The following populations are defined: 
Population Description  
Enrolled  All participants who sign the informed consent and/or assent 
ITT All participants who receive at least one dose of the study drug 
Safety  All participants who receive  at least 1 dose of the study drug and 
has at least one post -treatment observation  
 
9.4. Statistical Analyses  
The statistical analysis plan will include a more technical and detailed description of the statistical 
analyses described in this section. This section is a summary of the planned statistical analyses of 
the primary and secondary endpoints 
9.4.1. Primary Endpoint: Safety  
Safety variables will be presented descriptively . Details will be described in the Statistical Analysis 
Plan (SAP).   
9.4.2. Secondary Endpoints  
The effects of teplizumab treatment on the level of  C-peptide measured during the MMTT will be 
evaluated and compared to the results with historical control data. The HbA1c levels and insulin 
use will be described descriptively. The frequency of exhausted T  cells ( CD8+ TIGIT+ KLRG1+ 
T cells ), including the effect of anti-drug antibodies, will be described descriptively. 
Additional analyses may be performed and will be specified in the SAP. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   41 9.4.3. Handling Missing/Discontinued Participants   
An intent -to-treat (ITT)  approach will be used. Participants will not be replaced.  All data acquired 
prior to termination for the reasons outlined below will be included in the analys es unless the 
participant withdraws consent. Every effort will be made to conduct the Early Termination  visit 
with the participant and participants will be followed clinically until, if applicable, all AEs resolve.  
9.5. Interim Analyses  
An interim analysis is not planned. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   42 10. Supporting D ocumentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1. Study -Specific Design Considerations  
Potential participants will be fully informed of the risks and requirements of the study and, during 
the st udy, participants will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given and without penalty or loss of benefits to which 
they would otherwise be entitled. Only participants who are fully able to understand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntarily will be 
enrolled. 
When referring to the signing of the ICF, the terms legal guardian and legally acceptable 
representative refer to the legally appointed guardian of the child with authority to authorize 
participation in research. For each participant, his or her parent(s) (preferably both parents, if 
available) or legally acceptable representative(s), as required by local regulations, must give written consent (permission) according to local requirements after the nature of the study has been 
fully explained and before the performance of any study- related assessments. Assent must be 
obtained from children (minors) capable of understanding the nature of the study, typically participants 7 years of age and older, depending on the institutional policies. For the purposes of 
this study, all ref erences to participants who have provided consent (and assent as applicable) 
refers to the participants and his or her parent(s) or the participant's legal guardian(s) or legally acceptable representative(s) who have provided consent according to this process. Minors who 
assent to a study and later withdraw that assent should not be maintained in the study against their 
will, even if their parents still want them to participate.  
10.1.2. Investigator Responsibilities 
The Investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country- specific requirements.  
Good Clinical Practice is an international ethical and scientific quality standar d for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of study participants are protected, consist ent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible. 
10.1.3. Regulatory and Ethical Considerations 
Before the start of the study, the Investigator (or Sponsor where required) will provide the IEC/IRB 
with cu rrent and complete copies of the following documents (as required by local regulations): 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   43 • Final protocol and, if applicable, amendments 
• Sponsor-approved ICF (and any other written materials to be provided to the participants) 
• IB (or equivalent information) and amendments/addenda 
• Sponsor-approved recruiting materials 
• Information on compensation for study- related injuries or payment to participants for 
participation in the study, if applicable 
• Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB) 
• Information regarding funding, name of the Sponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for participants  
• Any other documents that the IEC/ IRB requests to fulfill its obligation  
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely administrative, with no consequences for 
participants, data or  study conduct, unless required locally), the ICF, applicable recruiting 
materials, and participant compensation programs, and the Sponsor has received a copy of this 
approval. This approval letter must be dated and must clearly identify the IEC/IRB and th e 
documents being approved. 
10.1.4. Informed Consent Process  
Each participant and a legally acceptable representative must give written consent according to 
local requirements after the nature of the study has been fully explained. The ICF(s) must be signed 
before  performance of any study- related activity. The ICF(s) and assent form that is/are used must 
be approved by both the Sponsor and by the reviewing IEC/IRB and be in a language that the 
participant can read and understand. The informed consent should be in a ccordance with principles 
that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, and Sponsor policy. 
Before enrollment in the study, the Investigator or an authorized member of the study- site 
personnel must explain to potential participants and their legally acceptable representatives the 
aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any 
discomfort participation in the study may entail. Participants will be informed that their 
participation is voluntary and that they may withdraw consent to participate at any time. They will 
be informed that choosing not to participate will not affect the care the participant will receive for 
the treatment of his or her dis ease. Participants will be told that alternative treatments are available 
if they refuse to take part and that such refusal will not prejudice future treatment. Finally, they will be told that the Investigator will maintain a participant identification reg ister for the purposes 
of long- term follow up if needed and that their records may be accessed by health authorities and 
authorized S ponsor personnel without violating the confidentiality of the participant, to the extent 
permitted by the applicable law(s)  or regulations. By signing the ICF/assent, the participant and 
legally acceptable representative are authorizing such access. It also denotes that the participant 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   44 agrees to allow his or her study physician to recontact the participant for the purpose of obtaining 
consent for additional safety evaluations.  
The participant and legally acceptable representative will be given sufficient time to read the ICF 
and the opportunity to ask questions. After this explanation and before entry into the study, 
assent/co nsent should be appropriately recorded by means of the participant's and his or her legally 
acceptable representative's personally dated signature. After having obtained the assent/consent, a copy of the ICF must be given to the participant and his or her legally acceptable representative.  
If the participant or legally acceptable representative is unable to read or write, an impartial witness should be present for the entire informed consent process (which includes reading and explaining 
all written informa tion) and should personally date and sign the assent/ICF after the oral consent 
of the participant or legally acceptable representative is obtained.  
10.1.5. Data Protection 
The collection and processing of personal data from participants enrolled in this study wil l be 
limited to those data that are necessary to fulfill the objectives of the study.  The objectives of the 
study and the nature and detail of the personal data to be recorded by the Sponsor as a consequence 
of study participation will be explained to each  study participant (or their legally acceptable 
representative) in the ICF and during the consent process. 
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. In Europe the Study 
will be conducted in compliance with Regulation (EU) 2016/679 “General Data Protection Regulation”. Appropriate technical and organizational measures to protect the personal data 
against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities r equire access to 
participants’ personal data shall be approved by the local IEC/IRB and shall agree to keep the 
participants ’ personal data confidential. 
The informed assent/consent obtained from the participant and his or her legally acceptable representative shall include explicit consent for the processing of personal data and for the 
Investigator/institution to allow direct access to his or her original medical records (source 
data/documents) for study- related monitoring, audit, IEC/IRB review, and regulatory authority 
inspection. This consent also addresses the transfer of the data to other entities and to other countries. 
The participant has the right to request access to his or her personal data and the right to request 
rectification of any data that are not correct or complete. Details of which party to contact in respect 
of such requests shall be included in the ICF and in the consent process. Reasonable steps will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   45 In addition to the se rights, a participant  may restrict the processing of incorrect data, request a 
copy of the data or ask for them to be transferred to a third party (portability). A participant can 
also withdraw consent on the data , in which case no further information about the participant  will 
be collected from that moment on ward . 
Any limitation placed upon the pa rticipant’s right to erasure of their personal data from study 
records resulting from the need to conduct the study in compliance to locally applicable regulations 
and laws shall be explained in the ICF and in the consent process. 
Exploratory research is not conducted under standards appropriate for the return of data t o 
participants. In addition, the Sponsor cannot make decisions as to the significance of any findings 
resulting from exploratory research. Therefore, exploratory research data will not necessarily be 
returned to participants or Investigators, unless required by law or local regulations. Privacy and 
confidentiality of data generated in the future on stored samples will be protected by the same standards applicable to all other clinical data.  
10.1.5.1. Sample  and Data Storage 
Samples collected from participants in this  study may be stored for up to 15 years or more (or 
according to local regulations) for additional research. Samples can be used to understand the 
effects of teplizumab on Type 1 diabetes, differential drug responders, and to develop tests/assays 
related t o teplizumab or other autoimmune conditions. The research may begin at any time during 
the study or the post-study storage period.  
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Participants may withdraw their consent for their samples to be 
stored for research .   
10.1.5.2. Use of Information and Publication 
All information, including but not limited to information regarding teplizumab  or the Sponsor's 
operations (eg, patent application, formulas, manufacturing processes, basic scientific data, prior clinical data, formulation information) supplied by the Sponsor to the Investigator and not 
previously published, and any data, including exploratory biomarker research data, generated as a result of this study, are considered confidential and remain the sole property of the Sponsor. The 
Investigator agrees to maintain this information in confidence and use this information only to 
accomplish this study and will not use it for other purposes without the Sponsor's prior written 
consent. 
The Investigator must agree to send to the Sponsor for review all manuscripts, abstracts and 
presentations using data from this study prior to their submission for publication. The Sponsor 
reserves the right to delete from such materials any part or parts deemed to be confidential or 
proprietary. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   46 The Investigator understands that the information developed in the study will be used by the 
Sponsor in connection with the continued development of teplizumab , and thus may be disclosed 
as required to other clinical investigators or regulatory agencies. To permit the information derived 
from the clinical studies to be used, the Investigator is obligated to provide the Sponsor wi th all 
data obtained in the study. 
The results of the study will be reported in a Clinical Study Report generated by the Sponsor and 
will contain data from all study sites that participated in the study as per protocol. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study will be used to determine a coordinating Investigator. Results of  exploratory analyses 
performed after the Clinical Study Report has been issued will be reported in a separate r eport and 
will not require a revision of the Clinical Study Report. Study participant identifiers will not be 
used in publication of results. Any work created in connection with performance of the study and 
contained in the data that can benefit from copyright protection (except any publication by the 
Investigator as provided for below) shall be the property of the Sponsor as author and owner of 
copyright in such work. 
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the Sponsor shall have the right to publish such primary (multicenter) data and 
information without approval from the Investigator. The Investigator has the right to publish study 
site-specific data after the primary data are published . If an Investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the Sponsor for review 
at least 60  days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, pos ter presentations, or other materials. If requested by the Sponsor in 
writing, the Investigator will withhold such publication for up to an additional 60 days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity or regulatory compliance, the Sponsor will review these issues with the Investigator. The Sponsor 
will not mandate modifications to scientific content and does not have the right to suppress information. For multicenter study designs and substudy approaches, secondary results generally 
should not be published before the primary endpoints of a study have been published. Similarly, Investigators will recognize the integrity of a multicenter study by not submitting for publication 
data derived from the individual study site until the combined results from the completed study have been submitted for publication, within 12 months of the availability of the final data (tables, 
listings, graphs), or the Sponsor confirms there will be no multicenter study publication. 
Authorship of publications resulting from this study will be based on the guidelines on authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals, which state that the named authors must have made a significant contribution to the 
design of the study or analysis and interpretation of the data, provided critical review of the paper, 
and given final approval of the final version. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   47 10.1.6. Registration of Clinical Studies and Disclosure of Results  
The Sponsor will register and disclose the existence of , and the results of clinical studies as 
required by law. 
10.1.7. Required  Pre- study Documentation  
The following documents must be provided to the Sponsor before shipment of study drug to the 
study site: 
• Protocol and amendment(s), if any, signed and dated by the P rincipal Investigator 
• A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, participant compensation programs. This approval must clearly identify the specific protocol by title and number and must be signed (or sealed, where appropriate per local regulations) by the chairman or authorized designee. 
• Name and address  of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from  the IEC/IRB, a general statement may be substituted for this list. If an Investigator or 
a member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opinion of the study. 
• Regulatory authority approval or notification, if applicable 
• Signed and dated statement of Investigator (eg, Form FDA 1572), if applicable 
• Documentation of Investigator qualifications (eg, curriculum vitae)  
• Completed Inves tigator financial disclosure form from the Principal Investigator, where 
required  
• Signed and dated clinical trial agreement, which includes the financial agreement  
• Any other documentation required by local regulations 
 The following documents must be provi ded to the Sponsor before enrollment of the first 
participant: 
• Completed I nvestigator financial disclosure forms from all sub -investigators 
• Documentation of sub- investigator qualifications (eg,  curriculum vitae)  
• Name and address of any local laboratory conducting tests for the study, and a dated copy 
of current laboratory normal ranges for these tests, if applicable 
Local laboratory documentation demonstrating competence and test reliability 
(eg, accreditation/license), if applicable  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   48 10.1.8. Monitorin g 
The Sponsor or designee  will use a combination of monitoring techniques  (eg, central, remote, or 
on-site monitoring)  to monitor this study. 
The Sponsor or designee will perform on -site monitoring visits as frequently as necessary. The 
monitor will record  dates of the visits in a study site visit log that will be kept at the study site. The 
first post -initiation visit will be made as soon as possible after enrollment has begun. At these 
visits, the monitor will compare the data entered into the CRF with th e source documents 
(eg, hospital/clinic/physician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
CRF are known to the Sponsor and study- site personnel and are accessible for verification by the 
Sponsor study- site contact. If electronic records are maintained at the study site, the method of 
verification must be discussed with the study-site personnel.  
Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review will 
be discussed with the study- site personnel. The Sponsor expects that, during monitoring visits, the 
relevant study- site personnel will be available, the source documents will be accessible, and a 
suitable environment will be provided for review of study- related documents. The monitor will 
meet with the Investigator on a regular basis during the study to provide feedback on the study 
conduct. 
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during these 
remote contacts, study-site personnel will be available to provide an update on the progress of the 
study at the site.  
Central monitoring will take place for data identified by the Sponsor or designee  as requiring 
central review.  
10.1.9. Data Quality Assurance 
Steps to be taken to ensure the accuracy and reliability of data i nclude the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the Investigator and 
study- site personnel before the study, and periodic monitoring visits by the Sponsor, and direct 
transmission of clinical l aboratory data from a central laboratory  into the Sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.  
Guidelines for CRF completion will be provided and reviewed with study- site personnel before 
the start of the study.  
Clinical monitors will review CRF for accuracy and completeness during on- site monitoring 
visits and after transmission to the Sponsor; any discrepancies will be resolved with the 
Investigator or designee, as appropriate . 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   49 10.1.10. Source Documentation  
At a minimum, source documents consistent in the type and level of detail with that commonly 
recorded at the study site as a basis for standard medical care must be available for the following: 
participant identification, eligibility, an d study identification; study discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy parameters as required by the protocol; record of all adverse events and follow -up of adverse events; concomitant medication; 
drug receipt/dispensing/return records; study drug administration information; and date of study 
completion and reason for early discontinuation of study drug or withdrawal from the study, if 
applicable.  
The author of an entry in the source documents should be identifiable.  
Specific details required as source data for the study and source data collection methods will be 
reviewed with the Investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document). 
The minimum source documentation requirement for Section 5.1, Inclusion Criteria and Section  
5.2, Exclusion Criteria , that specify a need for documented medical history is the complete history 
of medical notes at the site .  
Inclusion and exclusion criteria not requiring documented medical  history must be verified at a 
minimum by participant interview or other protocol required assessment (eg, physical 
examination, laboratory assessment) and documented in the source documents. 
An electronic source system may be utilized, which contains data  traditionally maintained in a 
hospital or clinic record to document medical care (eg, electronic source documents) as well as the 
clinical study -specific data fields as determined by the protocol. 
10.1.11. Case Report Form Completion  
Study- specific CRFs are prepar ed for each participant in electronic format.  
Electronic Data Capture (EDC) will be used for this study. The study data will be transcribed by 
study- site personnel from the source documents onto electronic CRFs (eCRF) via the secure EDC 
system in accordan ce with the study calendar, and within the timeframe agreed upon between the 
Sponsor and the study site. 
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the participant's source documents. Data must be entered into 
CRF in English. The CRF must be completed as soon as possible after a participant visit and the 
forms should be available for review at the next scheduled monitoring visit. 
When necessary, queries will be generated in the EDC system. If corrections to a CRF are needed 
after the initial entry into the CRF, this can be done in either of the following ways: 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   50 • Investigator and study personnel can make corrections in the EDC system at their own 
initiative o r as a response to a query (from the EDC system). 
• Sponsor or Sponsor delegate can generate a query for resolution by the Investigator and 
study-site personnel. 
All CRF entries, corrections, and alterations must be made by the Investigator or authorized study-
site personnel. The Investigator must verify that all data entries in the CRF are accurate and correct.  
Investigator will review, sign, and date completed CRFs at regular intervals as determined by the 
Sponsor. 
10.1.12. Record Retention  
In compliance with the ICH/GCP guidelines, the Investigator/institution will maintain all CRF and 
all source documents that support the data collected from each participant, as well as all study 
documents as specified in ICH/GCP Section  8, Essential Documents for the Conduct of a Clinical 
Trial, and all study documents as specified by the applicable regulatory requirement(s). The Investigator/institution will take measures to prevent accidental or premature destruction of these 
documents. 
Essential document s must be retained until at least 2  years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an ICH region or until at least 2 years have elapsed since the formal dis continuation of clinical 
development of the investigational product. These documents will be retained for a longer period 
if required by the applicable regulatory requirements or by an agreement with the Sponsor. It is 
the responsibility of the Sponsor to inform the investigator/institution as to when these documents 
no longer need to be retained. 
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will accept 
the responsibility. The Sponsor must be notified in writing of the name and address of the new 
custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents 
before having obtained written approval from the Sponsor. 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator/institution must permit access to such reports.  
 
10.1.13. Study Completion/Termination  
10.1.14. Study Completion/End of Study  
The study will be considered to have completed when the database is locked after the last 
participant’s last visit.  
The Investigator will notify the IRB/IEC when the study has been completed.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   51 10.1.15. Study Termination  
The Sponsor reserves the right to close a study site or terminate the study at any time for any reason 
at the sole discretion of the Sponsor. Study sites will be closed upon study completion. A study 
site is considered closed when all required documents and study supplies have been collected and 
a study-site closure visit has been performed. 
The Investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. Reasons for the early closure of a study site by the Sponsor or Investigator may include but are not 
limited to:  
• Failure of the Investigator to comply with the protocol, the requirements of the IEC/IRB 
or local health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by the Investigator  
Discontinuation of further study drug development 
10.1.16. On-Site Audits  
Representatives of the Sponsor's clinical quality assurance department or designee may visit the 
study site at any time during or after completion of the study to conduct an audit of the study in 
compliance with regulatory guidelines and company policy. These audits will require access to all 
study records, including source documents, for inspection. Participant privacy must, however, be 
respected. The Investigator and study- site personnel are responsible for being present and available 
for consultation during routinely scheduled study- site audit visits conducted by the Sponsor or its 
designees.  
Similar auditing procedures may also be conducted by agents of any regulatory body, either as 
part of a national GCP compliance program or to review the results of this study in support of a 
regulatory submission. The Investigator should immediately notify the Sponsor if he or she has been contacted by a regulatory agency concerning an upcoming inspection. 
 
  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   52 10.2. Appendix 2: Clinical Laboratory Tests Performed Locally  
The following clinical laboratory assessments will be performed locally  during the study as 
described in the Schedule of Events (Section 1.3): 
• Chemistry (sodium, potassium, chloride, CO2, glucose, BUN, creatinine) 
• Liver function tests (ALT, AST, LDH, alkaline phosphatase, total protein, albumin, total 
and direct bilirubin). Prior to each infusion, MMTT will be run locally in participants with 
Gilbert’s syndrome. 
• Hematology (complete blood count with differential and platelets) 
• HbA1c  
• Purified protein derivative (PPD) or IGRA test  for TB  
• Urine pregnancy test  for women of childbearing potential (WOCBP) 
• Antibodies to HIV, hepatitis B ( anti-hepatitis B core antibody, hepatitis B surface antigen ), 
hepatitis C (HCV)  
• Cytomegalovirus antibodies (CMV IgG and IgM). ,  
• Epstein -Barr virus antibodies (EBV IgG, IgM and EBNA). The Investigator must review 
the laboratory results, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be 
filed with the source documents. 
  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   53 10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1. Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered 
related to the study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. 
• Hypoglycemia and hyperglycemia will be reported as adverse events only in the case 
of requiring the assistance of others due to loss of consciousness or diabetic 
ketoacidosis ( DKA ). 
Unexpected AE:  
• An adverse event is considered unexpected when the nature (specificity) or severity of the event is not consistent with the risks described in the Investigator’s Brochure or the informed consent document. 
 
Events Meeting  the AE D efinition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, conside red clinically significant in the 
medical and scientific judgment of the investigator (i.e., not related to progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/o r intensity of the condition. 
• New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae. 
 
 
 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   54  
Events NOT  Meeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospit al). 
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
10.3.2. Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death 
b. Is life-threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were m ore severe.  
c. Requires inpatient hospitalization or prolongation of existing hospitalization 
• In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious. 
• Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   55 d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
• This definition is not intended to include experiences of relatively minor medical significance such as u ncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect  
f. Other situations: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life -threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious. 
• Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.
 
10.3.3. Definition of AESI  
The following types of AEs are considered AESIs:  
• All infections: viral, fungal, bacterial 
• Acute mononucleosis-like illness (eg, fever, pharyngitis, lymphadenopathy) 
• CMV viremia defined using DNA PCR testing and >10,000 copies per mL serum or 106 cells 
• EBV viremia defined using DNA PCR testing and >10,000 copies per mL serum or 106 cells 
• Herpes zoster or other conditions related to VZV 
• Primary infection with or reactivation of latent tuberculosis  
• Infections requiring IV antibiotic treatment 
• Demyelinating diseases  
• Malignancies including lymphomas 
• Severe hypoglycemic episodes that require assistance by another individual through the administration of oral or parenteral dextrose, glucagon or intervention 
• ≥ Grade 3 liver function abnormalities (AST, ALT, bilirubin) 
• ≥ Grade 3 thrombocytopenia (platelet counts less than 50,000/µL) 
• ≥ Grade 3 allergic/hypersensitivity reaction (anaphylaxis)  
• ≥ Grade 3 Rash 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   56 • ≥ Grade 3 cytokine- release syndrome  
• ≥ Grade 4 neutropenia (<500 PMN/µL on 2 consecutive evaluations performed on 
different days)  
10.3.4. Reporting and Follow-U p of AE and/or SAE  
AE and SAE R eporting 
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of particip ants, I nvestigators, and the Sponsor, and are mandated 
by regulatory agencies worldwide. The Sponsor has established Standard Operating Procedures 
in conformity with regulatory requirements worldwide to ensure appropriate reporting of safety 
information; a ll clinical studies conducted by the Sponsor or its affiliates will be conducted in 
accordance with those procedures.  
The determination of seriousness, severity and causality must be made by the physician 
Investigator who is qualified to review adverse event information, provide a medical 
evaluation of adverse events, and classify adverse events based upon medical judgment. 
An adverse event is any untoward medical occurrence in a clinical study participant  from the 
time they formally agree to participate in the study (eg, by providing informed consent /assent ) 
through their last study contact (eg, last visit or status update) . An adverse event does not 
necessarily have a causal relationship with the study drug. An adverse event can therefore be 
any unfavorable and unintended sign (including an abnormal finding), symptom, or disease 
temporally associated with the use of a study drug (investigational or non-investigational 
product) , whether or not related to tha t study drug (investigational or non-investigational 
product).  
This includes any occurrence that is new in onset or aggravated in severity or frequency from 
the baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.  
A treatment -emergent adverse event (TEAE) is defined as an AE that occurs after the first 
dose of study drug administration (Day 1) through the end of the study or early termination. 
The Investigator must follow all SAEs (inc luding serious AESIs) until resolution even if this 
extends beyond the study- reporting period. Resolution of a SAE is defined as the return to pre - 
treatment status or stabilization of the condition with the expectation that it will remain chronic. 
At any time after completion of the study, if an Investigator becomes aware of a serious adverse 
event that s/he suspects is related to study drug, the Investigator should report the event to the 
Pharmacovigilance contact . 
These events will be captured on the CRF  and reported to the Sponsor as described in Section 
8.4.1.1. Any event that meets serious adverse event criteria will be reported to the Sponsor 
within the appropri ate timeline as described in Section  8.4.1.4.  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   57 Events will be assessed and reported consistent with the ICH Guideline for Good Clinical 
Practice and per the guidance of the DHHS Office for Human Research Protections (OHRP).   
Event outcome and other follow-up information regarding the treatment and resolution of the 
event will be obtained and reported when available, if not known at the time the event is 
initially reported.  The follow -up information should contain sufficient detail to allow for a 
complete medical assessment of the case and an independent determination of possible causality.  
AESIs should be reported according to the requirements for SAEs.  
Assessment of Severity  
An assessment of severity grade for each AE will be made by the site Investigator according to 
the criteria set forth in the National Cancer Institute’s Common Terminology Criteria for 
Adverse Events Version 5.0.  This document (referred to herein as the “CTCAE V5.0”) provides 
a common language to describe levels of severity, to analyze and interpret data, and to articulate 
the clinical significance of all AEs. The Investigator should use clinical judgment in assessing 
the severity of events not directly experienced by the participant (eg, laboratory abnormalities). 
Adverse events will be graded according to National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0: 
• Grade 1  = Mild adverse event. 
• Grade 2  = Moderate adverse event.  
• Grade 3 = Severe adverse event.  
• Grade 4  = Life-threatenin g or disabling adverse event. 
• Grade 5  = Death   
 
Assessment of Causality  
The Investigator is required to provide an assessment of causality or relationship of adverse 
events to the study drug based on 1) temporal relationship of the event to the administration of 
study drug; 2) whether an alternative etiology has been identified; and 3) biological plausibility. 
The causality assessment categories that will be used for this study are described below.  
Causality assessments considered not related  to study drug: 
• Unrelated : The event is related to an etiology other than the study drug (the alternative 
etiology must be documented in the participant’s medical record). 
• Unlikely : The event is unlikely to be related to the study drug and likely to be related to 
factors other than study drug. 
Causality assessments considered related  to study drug: 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   58 • Possible : There is an association between the event and the administration of the study 
drug and there is a plausible mechanism for the event to be related to study drug; but 
there may also be alternative etiology, such as characteristics of the participant’s clinical status or underlying disease. 
• Probable : There is an association between the event and the administration of study drug, 
a plausible mechanism for the ev ent to be related to the study drug and the event could 
not be reasonably explained by known characteristics of the participant’s clinical status or an alternative etiology is not apparent. 
Definite : There is an association between the event and the admini stration of study drug, a 
plausible mechanism for the event to be related to the study drug and causes other than the 
study drug have been ruled out and/or the event re-appeared on re-exposure to the study drug. 
 
  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   59 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions:  
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below).  
 If fertility is unclear (e .g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP 
1. Premenarchal  
2. Premenopausal female with 1 of the following: 
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy 
 
For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry. 
Note: Documentation can come from the site personnel’s : review of the participant’s medical 
records, medical examination, or medical history interview. 
3. Postmenopausal female: 
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
o A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement [insert threshold if required (>40 IU/L or mIU/mL) or remove to allow for flexibility with different local 
thresholds for defining postmenopausal state] is required.  
• Females  on HRT and whose menopausal status is in doubt will be required to use one of 
the non- estrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
Male participants with partners who become pregnant  
• The investigator will attempt to collect pregnancy inf ormation on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive [study intervention]. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   60 • After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and submit it to the sponsor within [24 hours]  of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
Female Participants who become pregnant  
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study.  The initial information will be recorded 
on the appropriate form and submitted to the sponsor within [24 hours]  of learning of a 
participant's pregnancy.  
• The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, follow -up will not be required for 
longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy 
will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy for medical reasons will be reported as an AE or 
SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at >22 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
• Any post -study pregnancy related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study [will 
discontinue study intervention or be withdrawn from the study]  OR [may request 
continuation of study intervention. 
  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   61 10.5. Appendix 5: Abbreviations  
ADA  American Diabetes Association  
AE adverse event  
AESI  adverse event of special interest  
ALT  alanine aminotransferase 
AST  aspartate aminotransferase  
AUC  area under the time- versus -concentration curve  
BP blood pressure  
BSA  body surface area  
BUN  blood urea nitrogen  
CBC  complete blood count  
CD cluster of differentiation  
CMV  cytomegalovirus  
CRF  case report form(s) (paper or electronic as appropriate for this study)  
CRS  cytokine -release syndrome  
CTCAE  Common Terminology Criteria for Adverse Events  
DCCT  Diabetes Control and Complications Trial  
DKA  diabetic ketoacidosis  
DNA  deoxynucleic acid  
DPT -1 Diabetes Prevention Trial – Type 1  
EBNA  Epstein Barr nuclear antigen  
EBV  Epstein -Barr virus  
EDC electronic data capture  
ENDIT  European Nicotinamide Diabetes Intervention Trial  
ET early termination  
Fc fragment crystallizable region of an antibody/immunoglobulin molecule  
FcR receptor binding to the Fc component of antibody molecules  
FDA  Food and Drug Administration 
GCP  Good Clinical Practice  
HbA1c  hemoglobin A1c  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
HR heart rate  
IB Investigator Brochure  
ICF informed consent form  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   62 ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Ig immunoglobulin  
IGRA  interferon gamma release assay  
IHSG  International Hypoglycaemia Study Group  
IL interleukin  
IRB Institutional Review Board  
ITT intent to treat  
IV intravenous(ly)  
KD kilodalton  
LDH lactate dehydrogenase  
LFT liver function test 
mAb  monoclonal antibody  
MedDRA  Medical Dictionary for Regulatory Activities  
MHC  major histocompatibility complex  
MMTT  mixed meal tolerance test  
NAb  neutralizing antibody  
NCI National Cancer Institute  
NSAID  nonsteroidal anti -inflammatory drug  
PBMC  peripheral blood mononuclear cell  
PCR  polymerase chain reaction  
PK pharmacokinetic(s)  
PMN  polymorphonuclear leukocyte  
PPD purified protein derivative  
PVC  polyvinyl  chloride  
RNA  ribonucleic acid  
RR respiratory rate  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SD standard deviation  
SUSAR  suspected unexpected serious adverse reaction  
TEAE  treatment -emergent adverse event  
T1D type 1 diabetes  
TN-10 Anti- CD3 Monoclonal Antibody (Teplizumab) for Prevention of Diabetes in Relatives At -Risk 
for Type 1 Diabetes Mellitus Trial 
TB tuberculosis  
TCR  T cell receptor  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   63 TEAE  treatment -emergent adverse event  
U unit 
ULN upper limit of normal range  
VZV varicella zoster virus  
WBC  white blood cell  
ZnT8  zinc transporter 8  
  
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   64 11. References
Atkinson MA. ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of 
investigating the autoimmune basis for type 1 diabetes: why can’t we prevent or reverse this 
disease? Diabetes. 2005;54(5):1253-63. 
Diabetes 
Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The 
effect of intensive treatment of diabetes on the development and progression of long-t erm 
complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. 
EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in 
Europe. Lancet. 
2000;355(9207):873-876.G ale EA, Bingley 
PJ, Emmett CL, Collier T, 
European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European 
Nicotinamide Diabetes Intervention Trial 
(ENDIT): a randomised controlled trial of 
intervention before the onset of type 1 diabetes. Lancet 2004;363(9413):925-931. 
Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 
diabetes: two-y ear results from the randomized, placebo-controlled Protégé trial. Diabetes. 
2013;62(11):3901-3908. 
Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 
1 diabetes mellitus. N Engl J Med. 
2002;346(22):1692-1698. 
Herold KC, Gitelman SE, Umest M et al.  A single course of anti-CD3 monoclonal antibody 
hOKT3γ1(Ala-A la) results in improvement in C-p eptide responses and clinical parameters for at 
least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1-7. 
Herold KC, Gitelman SE, 
Ehlers MR, et al. Teplizumab (anti-C D3 mAb) treatment preserves C-
peptide responses in patients with new-onset type 1 diabetes in a randomized controlled 
trial: metabolic and immunologic features at baseline identify a subgroup of responders. 
Diabetes. 2013(a);62(11):3766-3774. 
Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide 
responses in participants with type 1 diabetes after the new-onset period: a randomised 
controlled trial. Diabetologia. 2013(b);56(2):391-400. 
Herold 
KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at 
Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. 
Imperatore G, 
Mayer-Davis EJ, Orchard 
TJ, Zhong VW. Prevalence and Incidence of Type 1 
Diabetes Among Children and Adults in the United States and Comparison With Non-U .S. 
Countries. Chapter 2 in Diabetes in 
America, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell 
MA, Eberhardt MS, Meigs 
JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, 
Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. 
Bethesda, MD, National Institutes of Health, NIH Pub No. 17-1468, 2018.  http://
www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-i n-america-3 rd-edition. 
Accessed on September 28, 2019.  
International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 
mg/dL) 
Should Be Reported in Clinical Trials: A Joint Position Statement of the 
American Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care. 2016;dc162215. 
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
Provention Bio, Inc.   65 Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy 
in new-onset type 1 diabetes. N Engl J Med. 2005 Jun 
23;352(25):2598-2608. 
Kuhtreiber WM, Washer SL, Hsu 
E, et al. Low levels of C-p eptide have clinical significance for 
established Type 
1 diabetes. Diabet Med. 2015 Oct;32(10):1346-1353. 
Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. I
mpact of C-p eptide preservation 
on metabolic  and clinical outcomes in the Diabetes  Control and Complications Trial. 
Diabetes. 2014;63(2):739-748. 
Livingstone SJ, Levin D, Looker HC, et al. Estimated
 life expectancy in a Scottish cohort 
with type 1 diabetes, 2008-2010. JAMA. 2015;313(1):37-44. 
Long SA, Thorpe J, DeBerg HA, 
et al. Partial exhaustion of C D8 T cells and clinical response to 
teplizumab in new-onset type 1 diabetes. Sci 
Immunol. 2016;1(5). pii: eaai7793. 
Mach H, Middaugh CR, Lewis RV. Statistical determination of the average values o f the 
extinction coefficients of tryptophan and tyrosine in native proteins. Anal Biochem. 
1992;200(1):74-80. 
Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young 
adults with type 1 diabetes in relation to age at  onset: a nationwide, register-based cohort 
study. Lancet. 2018;392(10146):477-486. 
Riley WJ, Maclaren NK, Krischer J, et al. A prospective study of the development of diabetes in 
relatives of patients with insulin -dependent diabetes. N Engl J Med. 1990;323(17):1167-1172. 
Sherr J, Sosenko J, Skyler JS, Herold 
KC. Prevention of type 1 diabetes: the time has come. Nat 
Clin Pract Endocrinol Metab. 2008;4(6):334-343. 
 
Sherry N, Hagopian W, Ludvigsson J, et al., Proté gé Trial Investigators. Teplizumab for treatment 
of type 1 
diabetes (Protégé study): 1-year results from a randomised, placebo-controlled 
trial. Lancet. 2011;378(9790):487-497. 
Sorensen JS, Johannesen J, Pociot F, et al. Residual β-cell function 3–6  years after onset of type 
1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care. 
2013;36(11):3454-3459. 
Sosenko JM, Palmer JP, Greenbaum et al. Patterns of metabolic progression to type 1 diabetes 
in the Diabetes
 Prevention  Trial-Type 1. Diabetes Care. 2006;29(3):643-649. 
Steffes MW, Sibley 
S, Jackson M, Thomas W.  Beta-cell function and the development of 
diabetes-836. related complications in diabetes control and complications trial.  Diabetes Care.  
2003;26(3 ):832-836.
VV-CLIN-0666755 1.0
CONFIDENTIAL  Protocol PRV -031-002, version 1.0 
 
Provention Bio, Inc.   66 INVESTIGATOR AGREEMENT  
I have read this protocol and agree that it contains all necessary details for carrying out this study. 
I will conduct the study as outlined herein and will complete the study within the time designated. 
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who assist in the conduct of this study. I will discuss this material with them to ensure that they are fully informed regarding the study drug, the conduct of the study, and the obligations of confidentiality.  
Coordinating Investigator (where required):  
Name (typed or printed):   
Institution and Address:   
  
  
Signature:   Date:   
   (Day Month Year)  
 
Principal (Site) Investigator:  
Name (typed or printed):   
Institution and Address:   
  
  
Telephone Number:   
Signature:   Date:   
   (Day Month Year)  
Sponsor's Responsible Medical Officer:  
Name (typed or 
printed):  
Organization:  Provention Bio, Inc  
Signature:   Date:   
   (Day Month Year)  
 
Note:  If the address or telephone number of the Investigator changes during the course of the 
study, written notification will be provided by the Investigator to the Sponsor, and a protocol 
amendment will not be required. 
 
VV-CLIN-0666755 1.0